NZ232685A - Tylosin biosynthetic pathway and genetically engineered organisms - Google Patents

Description

23 2 6 85 fpri ! Priority Dato(s) LXwrW? Opacification FiiecS: Cl; <5). ,C^?3..V:\?rr.\. j.Q. .f~cQ .&\2*]cK>| o Publication Date: P.O. Journal, No: \.5>SZt...

Under the provisions of Regulation 23 (1) the ...Mhx&liMl.

DIVIDED OUT OP APPLICATION No.: 219694 Date: 19 March 1987 NEW ZEALAND PATENTS ACT, 1953 Specification has been ante-dated to 19 .£L COMPLETE SPECIFICATION ANTIBIOTIC BIOSYNTHETIC GENEk- Initials \ t N . 1 S*i V- % © I / We. ELI LILLY AND COMPANY, a corporation of the State of Indiana, United States of America, having a principal place of business at Lilly Corporate Centre, City of Indianapolis, State of Indiana 46285, United States of America. hereby declare the invention for which I / we pray that a patent may be granted to me /us, and the method by which it is to be performed, to be particularly described in and by the following statement: - (followed by page la) 232685 ANTIBIOTIC BIOSYNTHETIC GENES The present invention provides antibiotic biosynthetic genes, DNA molecules containing sequences that encode such genes and the promoter and translational-activating sequences of such genes. The reader's attention is also directed to our related New Zealand Patent Specification No. 219 694 which provides a novel method for increasing the antibiotic-producing ability of an antibiotic-producing organism, the method involving transforming a microbial host cell with a DNA sequence that codes for the expression of a gene product that is rate-limiting in the desired antibiotic's biosynthetic pathway. The invention further provides recombinant DNA expression vectors, and transformed microbial host cells for use in the method disclosed.

The invention of New Zealand Patent Specification No. 219694 represents an early and significant commercial exploitation of recombinant DNA technology in antibiotic-producing organisms such as streptomycetes. Prior to that invention, the development and exploitation of recombinant DNA technology had been limited, for the most part, to the expression of specific polypeptides in E^. coli and, in some instances, mammalian cells. These advances led to the comparatively simple expression of heterologous gene products such as human insulin A and B chains, human proinsulin, human growth hormone, human protein C, human tissue plasminogen activator, bovine growth hormone, and several other compounds of potential value. In each case, heterologous gene expression is more or less independent and does not interact with, take part in, or modulate operative biosynthetic pathways. Recombinant DNA technology can now be applied to improve selected 2326 85 X-6808A -2- biosynthetic pathways for the expression of increased yields of antibiotics or antimicrobial precursors.

Most recombinant DNA technology applied to streptomycetes and other antibiotic-producing organisms 5 has been limited to the development of cloning vectors. Early attempts include the disclosures of Reusser U.S. Patent No. 4,332,898 and Manis et al. U.S. Patent Nos. 4,273,875; 4,332,900; 4,338,400; and 4,340,674. Transformation of streptomycetes was not disclosed or taught 10 in these early references. Improved vectors showing greater potential for use in antibiotic-producing organisms were disclosed, for example, by Fayerman et al. in U.S. Patent No. 4,513,086; and Nakatsukasa et al. in U.S. Patent Nos. 4,513,085 and 4,416,994. These 15 improved vectors contain markers that are selectable in streptomycetes, can be used to transform many important Streptomyces strains, and constitute the tools required for conducting more complicated gene cloning experiments.

One such experiment was recently reported by Hopwood et al., 1985, in Nature 314:642. Although Hopwood et al. reported the production of novel hybrid antibiotic pigments, the disclosure does not focus on increasing the antibiotic-producing ability or biosyn-25 thetic efficiency of a given host cell but instead describes the transferring of actinorhodin pigment biosynthetic genes from one Streptomyces strain to another.

The invention of NZ 219694 is particularly useful 30 because it allows commercial application of recombinant 232685; 6808A -3- DNA technology to streptomycetes and other antibiotic-producing organisms. Because over half of the clinically important antibiotics are produced by streptomycetes, it is especially desirable to develop methods that are applicable to these organisms. The invention further provides such methods and allows for the cloning of genes both for increasing the antibiotic-producing ability as well as for the production of new antibiotics and antibiotic precursors in an antibiotic-producing organism.

The present invention relates to the antibiotic biosynthetic genes, DNA molecules containing sequences which encode such genes and the promoter and translational-activating sequences of such genes.

For purposes of the present invention, the following terms are as defined: Antibiotic - a substance produced by a microorganism . that, either naturally or with limited chemical modification, inhibits or prevents the growth of or kills another microorganism or eukaryotic cell.

Antibiotic Biosynthetic Gene - a DNA segment that encodes an enzymatic activity or encodes a product that regulates expression of an enzymatic activity and which is necessary for an enzymatic reaction for converting primary metabolites to antibiotic intermediates, which also may possess antibiotic activity, and perhaps then to antibiotics.

Antibiotic Biosynthetic Pathway - the entire set of antibiotic biosynthetic genes and biochemical reactions necessary for the process of converting primary metabo o 232685 X-6808A -4- lites to antibiotic intermediates and then to antibiotics.

Antibiotic-Producing Microorganism - any organism, 5 including, but not limited to Actinoplanes, Actinomadura, Bacillus, Cephalosporium, Micromonospora, Penicillium, Nocardia, and Streptomyces, that either produces an antibiotic or contains genes that, if expressed, would produce an antibiotic.

Antibiotic Resistance-Conferring Gene - a DNA segment that encodes an activity that confers resistance to an antibiotic.

ApR - the ampicillin-resistant phenotype or gene conferring same.

Host Cell - an organism, including a viable protoplast thereof, which can be transformed with a recombinant DNA 20 cloning vector.

NmR - the neomycin-resistant phenotype or gene conferring same.

Operation of Antibiotic Biosynthetic Pathway - the expression of antibiotic biosynthetic genes and the related biochemical reactions required for the conversion of primary metabolites into antibiotics. 232685 X-6808A -5- Recombinant DNA Cloning Vector - any selectable and autonomously replicating or chromosomally integrating agent, including but not limited to plasmids and phages, comprising a DNA molecule to which additional DNA can be 5 or has been added. rep - as used in the Figures, a Streptomyces plasmid origin of replication.

Restriction Fragment.- any linear DNA generated by the action of one or more restriction•enzymes.

Sensitive Host Cell - a host cell, including a viable protoplast thereof, which cannot grow in the presence of 15 a given antibiotic without a DNA segment that confers resistance thereto.

Transformant - a recipient host cell, including a viable protoplast thereof, which has undergone transformation.

Transformation - the introduction of DNA into a recipient host cell,- including a viable protoplast thereof, that changes the genotype of the recipient cell. tsr - the thiostrepton-resistant phenotype or gene conferring same.

The plasmid and chromosomal maps depicted in -die Figures are drawn approximately to scale. However, 30 the tylosin biosynthetic genes, although linked, are X-6808A -6- 232685 scattered across a large segment of DNA. Therefore, detailed restriction site mapping data exists only for small regions of the large tylosin biosynthetic gene-containing DNA fragment. The maps do not necessar-5 ily provide an exhaustive listing of all the cut sites of a given restriction enzyme. The location of individual genes, represented by line segments on the maps, was determined by deletion mapping and thus only approximates the exact location of a given gene. 10 Figure 1 - The Tylosin Biosynthetic Pathway.

Figure 2 - Restriction Site and Function Map of Plasmid pHJL280.

Figure 3 - Restriction Site and Function Map of Plasmid pHJL284.

Figure 4 - Restriction Site and Function Map of Plasmid pHJL309.

Figure 5 - Restriction Site and Function Map of Plasmid pHJL311.

Figure 6 - Restriction Site and Function Map 20 of Plasmid pHJL315.

Figure 7 - Chromosomal Organization of the Tylosin Biosynthetic Genes.

As stated above the present invention relates to the antibiotic biosynthetic genes, DNA molecules containing sequences which encode such genes and the promoter and translational-activating sequences of such genes. In particular the present invention provides a DNA molecule containing the sequence that encodes a gene for the tylC, tylD, tylE, tylF, tylH, tylJ, tylK, tylL, or tylM biosynthetic genes and a DNA molecule containing the sequence which encodes the promoter and translational-activating sequence of the tylC, tylD, tylE, tylF, tylH, tylJ, tylK, tylL, or tylM, biosynthetic genes, in particular the present invention provides the tylF gene, a DNA molecule containing the sequence encoding the tylF gene, a DNA molecule containing the sequence which encodes the promoter and translational-activating sequence of the tylF gene, and a DNA molecule containing the sequence 232685 encoding the tylF promoter. By way of background we would direct the reader's attention to New Zealand Patent Specification No. 219694 which provides a method for increasing the antibiotic- or antibiotic precursor-producing ability of an antibiotic-producing microorganism, which comprises culturing a microorganism which produces an antibiotic or antibiotic precursor by a biosynthetic pathway, said microorganism being transformed with a DNA cloning vector or portion thereof which contains an antibiotic or antibiotic-precursor biosynthetic gene coding for expression of a rate-limiting enzyme or gene product of the biosynthetic pathway, under conditions suitable for cell growth, expression of the antibiotic or antibiotic-precursor biosynthetic gene and production of the antibiotic or antibiotic precursor, provided that the culturing process provides an increase in the antibiotic-producing ability of the microorganism.

The present invention provides related antibiotic biosynthetic genes, and DNA molecules containing sequences encoding such genes and the promoter and translational-activating-sequences thereof, which are suitable for use in methods of the type disclosed in New Zealand Patent Specification No. 219694.

Further, New Zealand Patent Specification No. 219694 provides a process for preparing an antibiotic, an antibiotic precursor, or a pharmaceuti-cally acceptable salt thereof, which comprises culturing a microorganism which produces, an antibiotic or antibiotic precursor through an antibiotic biosynthetic pathway, said microorganism being transformed with a DNA cloning vector, or portion thereof, in a culture medium containing assimilable sources of carbon, nitrogen and inorganic salts under aerobic fermentation conditions characterized in that the DNA cloning vector, or portion thereof, comprises an antibiotic biosynthetic gene which codes for the expression of a rate-limiting enzyme or gene product of the antibiotic biosynthetic pathway, said antibiotic biosynthetic gene being expressed under fermentation conditions providing for an increase in the antibiotic-producing ability of the microorganism. :,vw, r. 232685 X-6808A The methods of the invention of New Zealand Patent Specification No. 219694 are widely applicable to all antibiotic-producing organisms. The Following tables provide a non-exhaustive list of antibiotic producing organisms to which the invention may apply.

TrV^'% _ . c•-'-.■1 c'v/r-'^v-' -•« -■> , , 232665 X-6808A -9- TABLE I Aminocyclitol Antibiotic-Producing Organisms Organism Antibiotic Bacillus varxous species various aminocyclitols Micromonospora varxous specxes gentamycins Saccharopolyspora various species Streptomyces albogriseolus albus var. metamycinus aquacanus atrofaciens bikiniensis bluensis var- bluensis canus catenulae chrestomyceticus crystallinus erythro chromo g ene s var. narutoensis eurocidicus fradiae fradiae var. italicus various aminocyclitols neomycxns metamycin N-methyl hygromycin B hygromycins streptomycin bluensomycin ribosyl paromamine catenulin aminosidine hygromycin A streptomycin A16316-C hybrimycins and neomycins aminosidine 232 6 85 TABLE I (Continued) Organism Antibiotic o O Streptomyces galbus griseus griseoflavus hofuensis hygroscopicus hygroscopicus forma glebosus hygroscopicus var. limoneus hygroscopicus var. sagamiensis kanamyceticus kasugaensis kasugaspinus lavendulae lividus mashuensis microsporeus netropsis noboritoensis olivaceus olivoreticuli var. cellulophilus streptomycin streptomycin MA 1267 seldomycin complex hygromycins, leucanicidin, and hygrolidin glebomycin validamycins spectinomycin kanamycin A and B kasugamycins kasugamycins neomycin lividomycins streptomycin SF-767 II-AM31 hygromycins streptomycin destomycin A O 23 2 6 85 X-6808A o TABLE I (Continued) Organism Antibiotic poolensis rameus ribosidificus rimofaciens rimosus forma paromomycinus spectabilis tenebrarius Streptoverticillium flavopersicus streptomycin streptomycin SF733 destomycin A paromomycins and catenulin spectinomycin tobramycin and apramycin spectinomycin O o 232685 X-6808A TABLE II Ansamycin Antibiotic-Producing Organisms Organism Micromonospora various species Antibiotic various ansamycms Nocardia mediterranei rifamycin o Streptomyces collinus diastochromogenes galbus subsp. griseosporeus hygroscopicus hygroscopicus var. geldanus var. nova nigellus rishiriensis sp. E/784 sp. E88 spectabilis tolypophorous ansatrienes and napthomycins ansatrienes and napthomycins napthomycin B herbimycin geldamycin 21-hydroxy-25-demethyl 25-methy 1thiopro to streptovaricin mycotrienes actamycin and mycotrienes mycotrienes streptovaricins tolypomycin •■ft**.'*'****, t,lV» n 23 2685 X-6808A TABLE III Anthracycline and Quinone Antibiotic-Producing Organisms Organism Antibiotic Streptomyces caespitosus coelicolor coeruleorubidicus cyaneus flavogriseus galilaeus lusitanus peuceticus violochromogenes mitomycins A, B, and C actinorhodin daunomycin ditrisarubicin cyanocycline A aclacinomycin A, auramycins, and sulfurmycins napthyridinomycin daunomycin and adriamycin arugomycin cattleya chartreusis MM 4550, and MM 13902 thienamycin SF 1623 and cephamycin A and B •&£' ..

Wt&'V* ■ '^-y, t■**£;•-. .. •** 232685 X-6808A TABLE IV p-Iactam Antibiotic-Producing Organisms Organism Antibiotic Agrobacterium various p-lactams Cephalosporium acremonium penicillins and cephalosporins Chromobacterium Gluconobacter various p-lactams various p-lactams Nocardia lactamadurans uniformis cephamycin C nocardicin o Penicillium chrysogenum Serratia various penicillins and other p-lactams various p-lactams antibioticus argenteolus clavulanic acid asparenomycin A, f ^ r) 232685 X-6808A 6 TABLE IV (Continued) Organism Antibiotic Streptomyces .'cinnamonens i s clavuligerus clavulanic fimbriatus flavovirens flavus fulvoviridis griseus halstedi heteromorphus hygroscopicus lipmanii olivaceus panayensis rochei sioyaensis sp. OA-6129 sp. KC-6643 virido chromogenes vadayamensis cephamycin A and B PA-32413-I, cephamycin C, A16886A, penicillins cephalosporins, acid, and other clavams cephamycin A and B MM 4550 and MM 13902 MM 4550 and MM 13902 MM 4550 and MM 13902 cephamycin A and B and carpetimycin A and B cephamycin A and B C2081X and cephamycin A and B deacetoxycephalosporin C cephamycin, penicillin N, 7-methoxycephalosporin C, A16884, MM4550, MM13902 epithienamycin F, MM 4550, and MM 13902 C2081X and cephamycin A and B cephamycin A and B MM 4550 and MM 13902 OA-6129A carpetimycin A cephamycin A and B WS-3442-D 23268 & X-6808A -16- TABLE V Macrolide, lincosamide, and Streptogramin Antibiotic-Producing Organisms o G o Organism Micromonospora ^ rosaria Streptomyces albireticuli albogriseolus albus albus var. coilmyceticus ambofaciens antibioticus - avermitili's bikiniensis bruneogriseus caelestis cinerochromogenes cirratus deltae djakartensis erythreus eurocidicus eurythermus fasciculus Antibiotic rosaramicm carbomycin mikonomycin albomycetin coleimycin spiramycin and fororaacidin D oleandomycin avermectins chalcomycin albocycline M188 and celesticetin cineromycin B cirramycin deltamycins niddamycin erythromycins methymycin angolamycin amaromycin 232 6 85 X-6808A -17- TABLE V (Coatinued) Organism Antibiotic Streptomyces felleus fimbriatus flavochromogenes fradiae fungicidicus fungicidicus var. espinomyceticus furdicidicus goshikiensis griseofaciens griseoflavus griseofuscus . griseolus griseospiralis griseus griseus ssp. sulphurus halstedi hygros copicus hygroscopicus subsp. aureolacrimosus kitastoensis lavendulae lincolnensis argomycin and picromycin amaromycin amaromycin and shincomycins tylosin NA-181 espinomycins mydecamycin bandamycin PA133A and B acumycin bundlin griseomycin relomycin borrelidin bafilomycins carbomycin and leucanicidin tylosin milbemycins leucomycin A^ and josamycin aldgamycin lincomycin o 232685 X-6808A TABLE V (Continued) Organism Antibiotic O o loidensis macrosporeus maizeus mycarofaciens narbonensis narbonensis var. josamyceticus olivochromogenes platensis rimosus rochei rochei var. volubilis roseochromogenes roseocitreus spini chromo genes var. suragaoensis tendae thermotolerans venezuelae violaceoniger vernamycin A and B carbomycin ingramycin acetyl-leukomycin, and espinomycin josamycin and narbomycin leucomycin A^ and josamycin oleandomycin platenomycin tylosin and neutramycin lankacidin and borrelidin T2636 albocycline albocycline kuj imycins carbomycin carbomycin methymycins lankacidins and lankamycin o 232 6 85 X-6808A TABLE VI Miscellaneous Antibiotic-Producing Streptomyces Antibiotic Type Streptomyces Species Antibiotic amino acid analogues sp. cycloserine cyclopentane ring-containing ' coelicolor erythrochromogenes kasugaensis violaceoruber methylenomycin A sarkomycin aureothricin and thiolutin methylenomycin A nitro-containing venezuelae chloramphenicol polyenes griseus nodosus noursei candicidin amphotericin B nystatin tetracyclines aureofaciens rimosus tetracycline, chlor tetracycline, demethyltetra eyeline, and demethylchlortetra cycline oxytetracycline v3* ft ▼ >;z:j 232685.

X-6808A TABLE VII Nucleoside Antibiotic-Producing Organisms Organism Corynebacterium michiganese pv. rathayi Antibiotic tunicamycin analogues Nocardia candidus pyrazofurin Streptomyces antibioticus chartreusis griseoflavus var. thuringiensis griseolus lysosuperificus ara-A tunicamycin streptoviridans sinefungin tunicamycin o rs 232685, X-6808A TABLE VIII Peptide Antibiotic-Producing Organisms Organism Antibiotic Actinoplanes missouriensis , teichomyceticus Bacillus various species actaplanin teicoplanin bacitracin, polymixin, and colistin Nocardia candidus lurida orientalis A-35512 and avoparcin ristocetin vancomycin O "30 Streptomyces antibioticus aureus canus eburosporeus ha ranoma chiens i s pristinaespiralis roseosporus toyocaensis virginiae actinomycin thiostrepton amphomycin LL-AM374 vancomycin pristinamycin lipopeptides, such as A21978C A47934 A41030 J'™''. V vV'*^Vti*-^-J-S .<*'.« ?«v>yi" I- ;i-",-i-.;V *._> V vw' 232685 X-6808A O TABLE IX Polyether Antibiotic-Producing Organism Organism Antibiotic Actinomadura various specie^ o.ligosporus Dactylosporangium various species various polyethers A80190 various polyethers Nocardia various species various polyethers O o ' 25 Streptomyces albus aureofaciens bobili cacaoi var. asoensis chartreusis cinnamonensis conglobatus eurocidicus var. asterocidicus flaveolus gallinarius griseus A204, A28695A and B, and salinomycin narasin A80438 lysocellin A23187 monensin ionomycin laidlomycin CP38936 RP 30504 grisorixin 232685 X-6808A -23- TABLE IX continued Organism hygroscopicus lasaliensis longwoodensis mutabilis .pactum ribosidificus violaceoniger Streptoverticillium various species Antibiotic A218, emericid, DE3936, A120A, A28695A and B, etheromycin, and dianemycin lasalocid lysocellin S-11743a A80438 lonomycin nigericin polyethers The invention of New Zealand Patent Specification No. 219694 is best exemplified by transforming antibiotic-producing microorganisms with genes that code for enzymes that catalyze chemical reactions governing the conversion of primary metabolites into antibiotics. One such enzyme, macrocin 25 O-methyltransferase, catalyzes the final step in the biosynthesis of tylosin. Transforming tylosin-producing microorganisms with a macrocin O-methyltransferase-encoding 232685 X-6808A -24- gene, designated as tylF, results in an improved tylosin biosynthetic pathway because observed are increased levels of the tylF gene product in the transformed cells.

Accordingly, the invention of New Zealand Patent Specification No. 219694 also provides a method for increasing the tylosin or tylosin pre-cursor-producing ability of a tylosin-producing microorganism, which comprises culturing a microorganism which■produces tylosin or a tylosin precursor by a 10 biosynthetic pathway, said microorganism being transformed with a DNA cloning vector or portion thereof which contains tylosin or tylosin-precursor biosynthetic gene coding for expression of a rate-limiting enzyme or . gene product of the biosynthetic pathway, under condi-15 tions suitable for cell growth, expression of the tylosin or tylosin-precursor biosynthetic gene and production of the tylosin or tylosin precursor, provided that the culturing process provides an increase in the tylosin- or tylosin precursor-producing ability of the 20 microorganism.

The invention utilizes antibiotic biosynthetic genes as provided by the present invention, to increase the antibiotic-producing ability of an organism. A small number of antibiotic biosynthetic genes have been cloned, characterized, and 25 described in the relevant literature. Methods for isolating antibiotic biosynthetic genes have been developed, but one especially preferred method is. described in Baltz et al., U.S. Patent Application serial number 742,349, filed June 7, 1985,' (equivalent 30 to European Patent Application No. 86304239.6) which is incorporated by reference. The present tylosin o 232685 X-6808A -25- antibiotic biosynthetic genes used in a specific exemplification of the above referenced method initially were isolated from a \ library constructed in substantial accordance with the procedure described in Fishman et 5 al., 1985, J. Bacteriology 161:199-206.

A schematic representation of the tylosin biosynthetic pathway is presented in Figure 1; each arrow in Figure 1 represents a step which is catalyzed by one or more tylosin biosynthetic gene products. The 10 gene(s) responsible for each conversion is indicated above each arrow. Each genotypic designation may represent a class of genes that contribute to the same phenotype. A number of expression vectors.are used to exemplify the invention. These vectors comprise one or more tylosin biosynthetic genes and can be obtained from the Northern Regional Research Laboratories (NRRL), Peoria, Illinois 61604. Table X provides a brief description of each of the plasmids used.to exemplify the method Of the invention of New Zealand Patent 20 Specification No. 219694.

Table X Plasmids Comprising Tylosin Biosynthetic Genes X i cry 00 o 00 > Host/Designation Tylosin Gene(s) NRRL Accession No, Date of Deposit Map E. coli K12 HB101/pHJL280 D, E, F, H, J B- •18043 . February 18, 1986 Fig. 2 E. coli K12 HB101/pHJL284 c, F, J B- •18044 February 18, 1986 Fig. 3 E. coli K12 HB101/pHJL309 L, M B- •18045 February 18, 1986 Fig. 4 E. coli K12 HB101/pHJL311 c, F, J, K, H B- •18046 February 18, 1986 Fig.

E. coli K12 JM109/pHJL315 D, E, F, H, J B- •18047 February 18, 1986 Fig. 6 i N) I CM ro o» oo cn 232685 X-6808A -27- A number of Streptomyces fradiae strains are described which have mutant tylosin biosynthetic genes and, therefore, make much less tylosin than the strain from which they were derived. Table XI provides a brief description of these mutant strains. o % Table XI Streptomyces fradiae Mutants Defective in Tylosin Biosynthesis x i CTv 00 O 00 > 3 Strain Designation Mutant Gene ATCC* or NRRL Accession No.

GS15 tylF NRRL 18058 (deposited March 19, 1986) GS16 tylE ATCC 31664 (publicly available) GS28 tylF NRRL 18059 (deposited March 19, 1986) GS33 tylL GS48 tylD NRRL 12170 (publicly available) GS52 tylC NRRL 18060 (deposited March 19, 1986) GS62 tylM GS76 tylD . tylH NRRL ' 12171 (publicly available) GS85 tylK GS88 tylJ » K> 00 I *ATCC is the American Type Culture Collection, Rockville, MD 20852, and NRRL is the Northern Regional Research Laboratory, Peoria, IL 61604, to Cm ro ©> GO Cn 232685 X-6808A -29- As described in New Zealand Patent Specification No. 219694, plasmids pHJL280, pHJL284, and pHJL315 were used to transform Streptomyces fradiae GS15 and Streptomyces fradiae GS28. The GS15 and GS28 strains were prepared from S. fradiae C4 by nitrosoguanidine mutagen-5 esis. S. fradiae C4 was derived from S. fradiae T59235 (ATCC 19609) by mutagenesis. The GS15 strain makes almost no tylosin, and the GS28 strain makes low levels of tylpsin, as compared with the C4 strain. The decreased or nonexistent tylosin-producing ability of the 10 GS15 and GS28 strains is believed to result from mutations affecting the tylF gene, which encodes macrocin O-methyltransferase (MOMT). The MOMT enzyme, which is . required, for the conversion of macrocin to tylosin in the tylosin biosynthetic pathway, is frequently present 15 in reaction rate-limiting amounts in tylosin-producing strains. Plasmids pHJL280, pHJL284, .and pHJL315 remove this reaction limitation by providing a means for increasing both the copy number of the tylF biosynthetic gene and also the concentration of macrocin 20 O-methyl transferase available for tylosin biosynthesis. Accordingly, fermentation of £. fradiae GS15/pHJL280, S. fradiae GS15/pHJL284, S. fradiae GS15/pHJL315, S. fradiae GS28/pHJL284, S_. fradiae GS28/pHJL280, and S. fradiae GS28/pHJL315 for 72 hours results in about a 25 2-fold to a 6-fold increase in the production of macrocin O-methyl transferase over that produced in the C4 strain and a 120-fold increase over that produced in the GS28 strain.

Plasmid pHJL280 was also used to transform: 30 (1) Streptomyces fradiae GS16; (2) S. fradiae GS48; (3) 232685 X-6808A -30- £>.. fradiae GS76; and (4) S. fradiae GS88 which produce tylosin below detection limits and were derived by mutagenesis of the C4 strain. Untransformed strains GS16, GS48, GS76, and GS88 respectively produce a 5 defective enzyme or a rate-limiting amount of (1) the tylE, demethylmacrocin O-methyltransferase, enzyme; (2) the tylD enzyme, which is required for addition or biosynthesis of 6-deoxy-D-allose; (3) the tylH enzyme, which is required for oxidation of the C-23 methyl 10 position of tylactone; and (4) the tylJ enzyme. Untransformed strains GS16, GS48, GS76, and GS88, respectively, tend to accumulate demethylmacrocin, demycinosyl tylosin, 23-deoxydemycinosyl tylosin, and demycinosyl tylosin rather than the desired tylosin 15 antibiotic compound.

Plasmid pHJL280 provides a means for increasing the efficiency of the tylosin biosynthetic pathway by not only providing a non-defective gene but also by increasing the copy number of the tylD, tylE, tylH, and 20 tylJ biosynthetic genes and by increasing the intracellular amount of the products specified by these genes. The concentration of available tylE gene product, therefore, is increased, resulting in an elevated amount of enzyme capable of driving the conversion of 25 demethylmacrocin to macrocin to tylosin in the tylosin biosynthetic pathway. Similarly,, the concentration of available tylD, tylH, and tylJ gene products is also increased, resulting in the production of elevated amounts of the enzymes capable of driving the 6-deoxy-30 D-allose addition and C-23 oxidation of tylosin ° 232685 o X-6808A -31- precursors. Fermentation of Streptomyces fradiae GS16/pHJL280, S. fradiae GS48/pHJL280, S. fradiae GS76/pHJL280, and S. fradiae GS88/pHJL280 for 144-168 hours results in yields of tylosin that are significant-5 ly increased over that of the untransformed, low- tylosin-producing, mutant strains. Such transformed strains have higher enzyme levels of the particular enzymes encoded on plasmid pHJL280 than the parent C4 strain and thus further exemplify the invention.

Plasmid pHJL280 can be used to improve the tylosin-producing ability of any organism in which the tylD, tylE, tylF, tylH, or tylJ gene products (or any combination thereof) are present in rate-limiting amounts for tylosin biosynthesis.

• Plasmid pHJL284 was also used to transform Streptomyces fradiae GS52, a low tylosin-producing, mutant strain derived from the C4 strain that produces reaction-limiting amounts of an enzyme required for the biosynthesis or addition of mycarose to de-O-methyl-20 lactenocin. Thus, the tylosin biosynthetic pathway of Streptomyces fradiae GS52 tends to produce desmycosin rather than the desired tylosin antibiotic compound. Plasmid pHJL284 provides a means for improving the synthetic efficiency of this pathway by providing a 25 non-defective biosynthetic gene and by increasing the copy number of the tylC biosynthetic gene. The concentration of available tylC gene product in the transformed strain, therefore, is increased, resulting in the elevated production of enzyme capable of driving the 30 ' desired addition reaction. Accordingly, fermentation of O 232685 X-6808A -32- Streptomyces fradiae GS52/pHJL284 for 144-168 hours results in a level of tylosin production that is significantly increased over that of the untrans formed mutant strain and results in higher tylC enzyme levels than 5 those in the parent C4 strain. Plasmid pHJL284 was also used in the method to improve the tylosin-producing ability of Streptomyces fradiae GS88, a tylJ mutant, and thus can also be used in the method to improve the tylosin-producing ability of any 10 organism in which the tylC, tylF, or tylJ gene products (or any combination thereof) are present in rate-limiting amounts for tylosin biosynthesis.

Plasmid pHJL309 contains the tylL and tylM biosynthetic genes and was used in the method of New Zealand Patent Specification No. 219694 to 15 improve the tylosin-producing ability of Streptomyces fradiae GS33, a tylL mutant, and GS62, a tylM mutant.

Plasmid pHJL309 can also be used in the referenced method to improve the tylosin-producing ability of any organism in which the tylL or tylM gene products (or both) are 20 present in rate-limiting amounts for tylosin biosynthesis.

Plasmid pHJL311 contains the tylC, tylF, tylH, tylJ, and tylK biosynthetic genes and so was used in the referenced method to improve the tylosin-producing ability 25 of Streptomyces fradiae GS52, a tylC mutant; GS88, a tylJ mutant; GS15 and GS28, both of which are tylF mutants; and GS85, a tylK mutant. Plasmid pHJL311 can also be used in the method to improve the tylosin-producing ability of any organism in which the 30 tylC, tylF, tylE, tylJ, or tylK gene products (or any 232685 X-6808A -33- combination thereof) are present in rate-limiting amounts for tylosin biosynthesis.

Plasmid pHJL315 contains the tylD, tylE, tylF, tylH, and tylJ biosynthetic genes and so was used in the 5 present method to improve the tylosin-producing ability of Streptomyces fradiae GS48, a tylD mutant; GS88, a tylJ mutant; GS16, a tylE mutant; GS76, a tylD, tylH double mutant; and GS15 and GS28, both of which are tylF mutants. Plasmid pHJL315 can also be used in the 10 method to improve the tylosin-producing ability of any organism in which the tylD, tylE, tylF, tylH, or tylJ gene products' (or any combination thereof) are present in rate-limiting amounts for tylosin biosynthesis.

These results demonstrate that the vectors of the invention in New Zealand Patent Specification No. 219694 can increase the antibiotic-producing ability of an antibiotic-producing organism by providing higher enzyme or other gene product levels, as compared to an untransformed organism, of an enzyme or other gene 20 product that is rate-limiting in an antibiotic biosynthetic pathway. However, plasmid maintenance in an antibiotic-producing host cell sometimes requires significant expenditures of the cell's energy, energy that might otherwise be used to produce antibiotic.

Thus, certain microorganisms transformed with autonomously replicating vectors actually show a decrease in antibiotic-producing ability, even though the same vectors can increase the antibiotic-producing ability of other organisms. Not wishing the invention to o 232685 X-6808A -34- be bound or limited in any way by theory, this apparent anomaly can be explained by the fact that antibiotics are produced from primary metabolites, such as acetate, propionate, malonyl-CoA, methylmalonyl-CoA, and glucose, 5 by the action of specific enzymes. These enzymes are usually not present during the rapid growth phase of an organism and so do not rob the growing cell of needed compounds. As growth becomes limited by nutritional conditions, antibiotic biosynthetic genes are believed 10 to be activated, causing the synthesis of enzymes that redirect the flow of certain primary metabolites into antibiotic products.

The synthesis of antibiotics is also believed to be a dispensable function in antibiotic-producing 15 organisms because mutants blocked in the biosynthesis of antibiotics are viable and grow as well as the antibiotic-producing parent. Wild-type strains produce a relatively small amount of antibiotic, which is apparently adequate to provide the organism with a 20 selective advantage.

The development of industrial antibiotic producing strains from natural isolates involves many cycles of mutation and selection for higher antibiotic production. Because the synthesis of antibiotics drains 25 primary metabolites and cellular energy away from growth and maintenance functions, it is believed that selection for higher antibiotic production frequently occurs at the expense of the vitality of the organism. Thus, the generation of high antibiotic-producing strains involves 30 finely balancing the cells nutritional and energy 232685 X-6808A -35- resources between growth-maintenance functions and antibiotic production. As a consequence of this fine-tuning, high-yielding production strains tend to be extremely sensitive to factors that affect cellular 5 physiology. For example, introduction of autonomously-replicating vectors, notably multicopy plasmids, sometimes tends to decrease the antibiotic-producing ability of an organism that normally produces antibiotics at high levels. The mechanism of this inhibition is not 10 clear, but may occur at an early step in the biosynthesis of the antibiotic because measurable levels of antibiotic precursors do not accumulate under these conditions. In addition, autonomously replicating vectors may drain pools of precursors for DNA or RNA 15 synthesis or, in high copy number, may titrate DNA binding proteins, such as RNA polymerase, DNA polymerase, polymerase activators, or repressors of gene expression. Another frequent limitation of autonomously replicating vectors is spontaneous loss. Spontaneous 20 loss is especially problematical when the vector reduces growth rate as frequently occurs. Selection for a resistance marker on the plasmid can ensure the growth of homogeneous, plasmid-containing populations but can also disrupt the fine physiological balance (already 25 mentioned) of an antibiotic fermentation. Selection for unstable plasmids operates by killing or inhibiting the bacteria that lose the plasmid and can result in a reduced growth rate.

The negative effect, sometimes observed, of 30 autonomously replicating vectors on the 232685 X-6808A -36- antibiotic-producing ability of a microorganism is greatest in high-producing strains that are delicately balanced with respect to growth-maintenance functions and antibiotic production. The invention of New Zealand Patent Specification 5 No. 219694 overcomes this previously unrecognized problem of the negative effect of autonomous plasmid replication on high-producing strains by providing methods of culturing the transformed host,cell to facilitate identification of transformed cells containing integrated plasmid and, 10 in addition, by providing vectors with features that also facilitate detection of integration. Selecting a culturing procedure that results in integration is important in improving the antibiotic-producing- ability of highly selected and conventionally improved 15 antibiotic-producing organisms. Organisms or strains that have a low antibiotic-producing ability can be improved by transformation via either integration or autonomous vector replication. As those skilled in the art of fermentation technology will appreciate, .the . 20 greatest improvement in antibiotic-producing ability is shown when the present invention is applied to low antibiotic-producing strains.

Integration of plasmid DNA is readily accomplished by transforming a given antibiotic-producing 25 strain or mutant thereof according to standard transformation procedures, selecting or otherwise identifying the transformants, and then culturing the cells under conditions that do not require the presence of plasmid DNA sequences for the host cell to grow and replicate. 30 After several generations under non-selective 232685 X-6808A -37- conditions, certain cells will no longer contain free plasmid DNA, so by selecting for or otherwise identifying plasmid DNA sequences present in the host cell, one can identify host cells in which the plasmid DNA has 5 integrated into the chromosomal (genomic) DNA of the cell. This culturing technique to obtain integration of vector DNA is especially useful when used in conjunction with a vector that is inherently unstable in the transformed host cell, so that culturing without selective 10 pressure to maintain the vector generates segregants that are free of the plasmid. Bibb et al., 1980, Nature 384:526-531, describe a DNA sequence needed for stable inheritance of a vector, and a variety of vectors have been constructed that lack this stability sequence. 15 For instance, cloning vectors pHJL210 and pHJL401, which were used to construct the plasmids of New Zealand Patent Specification No. 219694 lack this stability sequence. Plasmid pHJL210 is disclosed in U.S. Patent Application Serial No. 639,566, filed August 10, 1984, (equivalent 20 to European Publication No. 176199). Plasmid pHJL401 is disclosed in U.S. Patent Application Serial No. 841,920, filed March 20, 1986, which is a continuation-in-part of Serial No. 763,172, filed August 7, 1985, (equivalent to European Application No. 86306011.7, filed August 5, 25 1986). As used, "unstable" refers to plasmids that are lost at high frequency by transformed cells only when those cells are cultured in the absence of selective pressure for plasmid maintenance because, for example, plasmids such as pHJL210 and pHJL401 are quite stable o 232685 X-6808A -38- when selective pressure is applied to the transformed host cell. When host cells transformed with stable vectors are cultured in the absence of selective pressure, the vector is not lost with the high frequency observed 5 with unstable vectors, and identification of integrants is made difficult by the great number of cells that still contain autonomously replicating plasmid even after growth under nonselective conditions. Selection for integrants is more fully described below. Once the 10 vector DNA has integrated into the chromosomal DNA of the host cell, one observes the maximum increase in antibiotic-producing ability for that host cell, because inhibition by autonomously replicating plasmid no longer occurs.

Integration of vectors containing cloned genes into the genome of the producing organism can be achieved in a number of ways. One way is to use a lysogenic bacteriophage or other phage vector that can integrate into the genome of the host strain. Another 20 approach is to use a plasmid vector carrying the cloned genes and to screen for integration of the recombinant plasmid into the host genome by a single recombination event between the cloned sequence and the homologous chromosomal sequence. Integration frequency of a vector 25 can be dramatically increased by adding DNA homologous to the genomic DNA of the host cell to the vector. As used "integration" refers both to a single recombination event, known as Campbell-type recombination, and also to a double-crossover event, which results in exchange of 30 genetic information between the vector and the r> 232685 X-6808A -39- chromosome. With double-crossover recombination, only a portion of the vector integrates into the chromosomal DNA.

For example, a plasmid carrying cloned tylosin 5 biosynthetic genes (tyl) could integrate into the Streptomyces fradiae genome by a single crossover between the tyl genes on the plasmid and the homologous tyl genes in the genome. Another option would be to put a non-tyl S. fradiae DNA sequence on the plasmid in • 10 addition to the cloned tyl genes and to screen for integration at the locus corresponding to the non-tyl sequence. The latter approach avoids the possible mutagenic effects of integration into the tyl sequences, but if double-crossover recombination is desired, the 15 vector should comprise the antibiotic biosynthetic genes flanked by separate sequences of homologous DNA.

To avoid the potentially adverse effects, however remote, of a recombinant plasmid (either autonomously replicating or integrated) on tylosin production, 20 • one can make use of the ability of Streptomyces fradiae to take up tylosin precursors from the culture medium and convert them to tylosin. In one fermentation of a tylosin-producing strain that had been transformed with plasmid pHJL280 and cultured to obtain integrants, only 25 a subpopulation (^18%) of the cells were thiostrepton resistant, which indicates the presence of plasmid pHJL280 sequences. However, this subpopulation contained multiple copies of the genes for two rate-limiting enzymes, demethylmacrocin-O-methyltransferase 30 (DMOMT) and macrocin-O-methyltransferase (MOMT), and 23268 X-6808A -40- consequently elevated (about 9 fold) levels of the two enzymes, and was able to convert all of the normally accumulated demethylmacrocin and macrocin to tylosin (see Table XIV).

Thus, one can develop specific strains of S. fradiae containing multiple copies of rate-limiting genes and high enzyme levels to act as converters of accumulated precursors to tylosin. These converter strains can be used in several different ways: (1) the 10 converter strain can be co-inoculated into the fermentor with the normal production strain at a low ratio of converter:producer; (2) the converter strain can be introduced into a production fermentation culture late in the cycle to convert intermediates; (3) the converter 15 strain can be kept in a separate "reactor"," to which the fermentation production broth from the producer strain would be added; or (4) the converter strain can be immobilized on a column, and fermentation broth from the producer strain passed through. Those skilled in the 20 art will recognize that having separate production and converting populations eliminates the adverse effects that recombinant plasmids sometimes have on antibiotic production in high antibiotic-producing strains.

Separate populations also eliminate vector 25 stability problems, because the converting strains can be grown in small vessels in which antibiotic selection or some other selection means for maintenance of the plasmid can be carefully regulated and controlled. In essence, the converting strain is a source of enzymes, 30 and the production of these enzymes at high level can be o 232685 X-6808A -41- approached in much the same way as production of proteins from recombinant plasmids in E. coli.

Of course, antibiotic production is only increased by the method described in New Zealand Patent Specification No. 219694 when 5 the transforming DNA comprises a gene that encodes the rate-limiting enzyme of the untransformed strain.

Various methods for determining the rate-limiting step in the biosynthesis of an antibiotic are known in the art (Seno and Baltz, 1982, Antimicrobial Agents and 10 Chemotherapy 21:758-763), but there is no need to identify the rate-limiting step when the entire set of antibiotic biosynthetic genes are available for introduction into the antibiotic-producing strain. If a rate-limiting enzyme is not known, the antibiotic-15 producing strain is transformed with the entire set of antibiotic biosynthetic genes, thus ensuring that, no matter what enzyme is rate-limiting, the transformed host cell will have higher levels of the rate-limiting enzyme than the untransformed host cell. Often, howev-20 er, the rate-limiting enzyme of an antibiotic biosynthesis pathway will be known, and the method described in New Zealand Patent Specification No. 219694 can be used to increase the antibiotic-producing ability of the organism by transforming the organism with a vector that encodes the 25 rate-limiting antibiotic biosynthetic enzyme.

For instance, the GS15 strain, which produces no readily detectable tylosin (the level of tylosin produced by these cells is below the detection limits for the assay used to determine tylosin levels) and the 30 GS28 strain, which produces very low levels of tylosin, 232685 X-6808A -42- contain tylF mutations, so that it is a relatively simple matter to identify the rate-limiting step in tylosin biosynthesis in these mutant strains. The strain from which the GS15 and GS28 strains were de-5 rived, designated Streptomyces fradiae C4, produces high levels of tylosin and accumulates relatively large amounts of macrocin, the immediate precursor of tylosin on which the tylF gene product acts to form tylosin. Other S. fradiae strains that produce even more tylosin 10 than the C4 strain accumulate even more macrocin than the C4 strain. These observations indicate that the tylF gene product is present in rate-limiting amounts for the biosynthesis of tylosin in high tylosin-producing strains. Transformation of these 15 macrocin-accumulating strains with a vector comprising the tylF gene followed by isolation of those transformants that only contain integrated copies of the vector yields transformants that produce more tylosin than the untransformed cells. The increase in tylosin 20 production observed in these transformants is related to the amount of macrocin that accumulates in the untransformed cells. It will be apparent to those skilled in the art that the transformants produced by the foregoing procedure might still contain 25 rate-limiting amounts of the tylF gene product, in which case a further increase of the tylF copy number would further increase tylosin yield, or the transformed strains might now contain rate-limiting amounts of yet another antibiotic biosynthetic enzyme, the level of o 232685 X-6808A -43- which could be made non-rate-limiting by the method of the pre'S'ent invention.

The invention of New Zealand Patent Specification No. 219694 therefore provides both a method and recombinant DNA cloning vectors for 5 increasing the production of an antibiotic by manipulation of antibiotic biosynthetic pathways. An illustrative antibiotic biosynthetic pathway involves the biosynthesis of tylosin, a complex macrolide produced by strains of Streptomyces fradiae, Streptomyces rimosus, and Strepto-10 myces hygroscopicus. Tylosin is composed of a 16-member branched lactone (tylonolide) to which three sugars (mycarose, mycaminose, and mycinose) are attached. The lactone is derived from two acetates, five propionates, and a butyrate by condensation of a propionyl-S-coenzyme 15 A molecule with two malonyl-S-coenzyme A molecules, four me thy lmalonyl-S-coenzyme A molecules, and an ethylmalonyl-S-coenzyme A molecule by a scheme believed analogous to that involved in fatty acid biosynthesis.

Lactone formation, sugar biosynthesis/attachment, and 20 the conversion of resultant intermediate compounds to tylosin are catalyzed by a series of gene-encoded enzymes. Cloning genes that code for such enzymes allows modification and improvement in the operational efficiency of the tylosin biosynthetic pathway and is 25 illustrative of the invention.

Illustrative tylosin biosynthetic genes of the present invention that can be used for purposes of the invention described above include, for example, the tylC, tylD, tylE, tylF, tylH, tylJ, tylK, tylL, and tylM, genes. Of this group, the 30 tylF gene is preferred because the macrocin 232685 X-6808A -44- O-methyltransferase enzyme encoded thereby appears to be rate-limiting in the tylosin biosynthetic pathway of most tylosin-producing strains. Macrocin accumulates to unacceptable levels under conditions of optimum fermen-5 tation of Streptomyces fradiae because of the rate- limiting steps catalyzed by the tylF gene product. The tylF enzyme catalyzes the conversion of macrocin to tylosin, as depicted in Figure 1 of the accompanying drawings. Over-production of the tylF gene product, 10 macrocin O-methyltransferase, results in the more efficient operation" of the tylosin biosynthetic pathway as indicated by increased, antibiotic yield and lower cost of fermentation.

Those skilled in the art will recognize that the invention of 15 New Zealand Patent Specification No. 219694 is not limited to the use of plasmids pHJL280, pHJL284, pHJL309, pHJL311, or pHJL315. The antibiotic biosynthetic genes provided by the present invention which are contained in these vectors can be excised in whole or in part and ligated into any number of different recombinant DNA cloning 20 vectors. For instance, digestion of plasmid pHJL280 with restriction enzymes BamHI and Bglll yields five BamHI-BamHI fragments with sizes of ~10.3 kb, ~6.54 kb, ~2.3 kb, 1.7 kb, and ~1.0 kb; two BamHI-BqIII fragments with sizes of ~2.9 kb and 2.0 kb; and one Bqlll-BqIII 25 fragment ~0.2 kb in size. The ^2.9 kb BamHI-BqIII fragment of plasmid pHJL280 contains the tylF gene.

Digestion of plasmid pHJL280 with restriction enzymes Bglll and EcoRI generates four fragments: an ^11.24 kb EcoRI-EcoRI fragment; an ^11.5 kb Bqlll-EcoRI fragment; 30 an ^4.0 kb EcoRI-Bglll fragment, and an ^0.2 kb 232685 X-6808A -45- Bglll-Bqlll fragment. The ~4.0 kb EcoRI-Bglll fragment of plasmid pHJL280 contains the tylE gene.

Digestion of plasmid pHJL284 with restriction enzymes BamHI and EcoRI generates three BamHI-BamHI 5 fragments with sizes of ~9.7 kb, ^2.3 kb, and ~1.0 kb; and four EcoRI-BamHI fragments with sizes of ^6.24 kb, ~4.3 kb, ^2.3 kb, and ~1.1 kb. The ~2.3 kb BamHI-EcoRI fragment of plasmid pHJL284 contains the tylF gene'. Digestion of plasmid pHJL284 with restriction enzyme 10 EcoRI generates two fragments with sizes of ~16.4 kb and ~10.54 kb; the ~16.4 kb fragment contains the tylF, tylC, and tylJ genes. The ~1.7 kb EcoRI-BamHI restriction fragment of plasmid pHJL311 comprises the tylK gene. The ^18.5 kb EcoRI restriction fragment, as well 15 as the ~8.3 kb BamHI-Kpnl restriction fragment, of plasmid pHJL309 contains the tylL and tylM genes.

Any of the aforementioned tyl gene-containing fragments can be ligated into other vectors to make vectors useful in the method of New Zealand Patent Specification No. 20 219694. Such other vectors include, for example, those vectors disclosed in U.S. Patent Nos. 4,468,462; 4,513,086; 4,416,994; 4,503,155; and 4,513,185; and also plasmids pIJlOl, piJ350, piJ702 (ATCC 39155), SCP2* (NRRL 15041), pHJL192, pHJL197, pHJL198, pHJL210, pHJL211, pHJL400, 25 pHJL401, pHJL302, pIJ922, pIJ903, pIJ941, pIJ940, and pIJ916. These vectors'replicate in Streptomyces fradiae and other tylosin-producing strains and are thus useful for cloning the present antibiotic biosynthetic genes. The "unstable" vectors described above are preferred 30 when integration of the vector is desired. 232685 X-6808A -46- Illustrative Streptomyces strains that can be used for purposes of the invention of New Zealand Patent Specification No. 219694 include, for example, S. fradiae, S. fradiae GS52, S- fradiae GS48, S. fradiae GS16, S. fradiae GS28, S. fradiae GS15, S. 5 fradiae GS76, S. rimosus, and S. hygroscopicus. Streptomyces hygroscopicus and S. rimosus are well known, having been deposited at the American Type Culture Collection (ATCC), Rockville, Maryland 20852. A number of strains of S. hygroscopicus can be obtained under the 10 accession numbers ATCC 27438, ATCC 21449, ATCC 15484, ATCC 19040, and ATCC 15420, and S. rimosus can be obtained under the accession number ATCC 10970. Of the Streptomyces taxa, S. fradiae GS16, fradiae GS15, and S. fradiae GS28 are preferred, especially for transfor-15 mation with plasmid pHJL280. Streptomyces fradiae is also an especially well known microorganism and several strains are available, on an unrestricted basis, from the Northern Regional Research Laboratory (NRRL),.

Peoria, Illinois 61604 and the ATCC under the respective 20 accession numbers NRRL 2702, NRRL 2703, and ATCC 19609.

The recombinant plasmids described in the invention of New Zealand Patent Specification No. 219694 each comprise one or more antibiotic biosynthetic genes as provided by the present invention. Unless part of a polycistron, each antibiotic biosynthetic gene normally comprises: (1) a 25 promoter that directs transcription of the gene; (2) a sequence that, when transcribed into mRNA, directs translation of the transcript; (3) a protein-coding sequence; and (4) a transcription terminator. Each of these elements is independently useful and can, through 30 the techniques of recombinant DNA technology, be used to 252685 X-6808A -47- form recombinant genes of great variety. As one example, the protein-coding sequence for the tylF gene can be linked to the promoter, translation-activating sequence, and transcription-terminating sequence from a 5 non-Streptomyces fradiae gene to form a recombinant gene that functions in the host from which the non-S. fradiae sequences were isolated. Such a novel gene could be used to produce a hybrid antibiotic if introduced into an organism that produced an antibiotic or antibiotic 10 intermediate that is not found in the tylosin pathway but that would serve as a substrate for the novel gene product. Similarly, the promoter and other regulatory elements of the tylF gene could be linked to the coding sequence of a non-tylosin antibiotic biosynthetic gene" 15 to prepare a hybrid gene that would function in S. fradiae. Thus, the individual elements of each of the antibiotic biosynthetic genes on each of the plasmids described herein comprise an important component of the invention.

For example, sequence data on the tylF nucleo tide sequence has identified the tylF promoter, which comprises an important aspect of the present invention. The sequence (only one strand of which is depicted for convenience) is shown below; the promoter and translation-25 activating sequence of the tylF gene is believed to reside in the sequence between residues 1 and 207 upstream from the translation start site. 9 «*\ 240CTJ99f y'u-, ' - ^X-feSOSA 232685 As an additional embodiment of the present invention t the gene sequence for the tylF gene is provided. In particular, the entire tylF gene, including the promoter and translation-activating sequence noted above, has been found to have the following sequence: 20 30 40 '-TTC GCG GGA TGG ATG CTG ACQ CGG GGG TCG GCC AGC AGC GCC CGG ACG 50 60 70 80 90 TGA TCT GGC GGG AGA TCA GCC AGA CCG GCG CCC CGT CCC ACA GCT CGG . 100 110 120 130 140 CCC GGG CGA TCG GCT CCT CCG CCC GGA GGG CGG CGT ACT GCT CGG GAG 150 " 160 170. 180 190 GGC TGA AGG GAC AGG TGC GGG CGA CCG GCC AGG CGA TGC TGC GCC GGC 200 210 220 230 240 CTG CGG CCC CGT CGG TGT CGT TGG CGC GTG CTG CGG GCA ACA GAA TCC 250 260 270 280 CCT TTT GTG ACG GGC GGG CGT CCC CGG ACG AGG ACA CGA CTC GCT GCG ^ 25 290 300 310 320 330 GCC TCA ACG AAA ACA CCG TGT CCG GTG CCC AGG CCA CGA ACG GTG ACC 340 350 GGT CTG TGT CAG GTC GCC CGT 360 370 380 GGT GAC GGG CTC CGG GGC GGC GGC GCG cT0M 232 6 85 n """ 390 400 410 420 430 GGC GGC CGA CCT TGA CAT ACC CGC GGC CGG GCT CCT CGT TCC GGC GCG ,-~N20 -"">25 440 450 460 470 480 GCC CGC GCC GAT AGC GTC CGT CCT CAC CGG CTC CGG CGT CCG CGT CCC 490 500 510 520 CGC CGG GAC GTG CCA CCT CTC CCG ACC CCG CGA GCC GAT CGA CCC GCT 530 540 550 560 570 ACT GGA GGA CCC GTG GCA .CCT TCC CCG GAC CAC GCC CGC GAT CTC TAC VAL ALA PRO SER PRO ASP HIS ALA ARG ASP LEU TYR 5 10 580 590 600 610 620 ATC GAG CTG CTG AAG AAG GTC GTC TCG AAC GTC ATC TAC GAG GAC CCC ILE GLU LEU LEU LYS LYS VAL VAL SER ASN VAL ILE TYR GLU ASP PRO 15 20 25 630 640 650 . 660 670 ACC CAT GTG GCG GGG ATG ATC ACC GAC GCG TCG TTC GAC CGG ACG TCC THR HIS VAL ALA GLY MET ILE THR ASP ALA SER PHE ASP ARG THR SER 35 40 680 690 700 710 720 CGT GAG AGC GGC GAG GAC TAC CCC ACG GTC GCC CAC ACG ATG ATC GGC ARG GLU SER GLY GLU ASP TYR PRO THR VAL ALA HIS THR MET ILE GLY 45 50 55 60 X .. -6808A 23268 J 730 740 750 760 CTC AAG CGT CTG GAC AAT CTC CAC CGG TGC CTC GCG GAC GTC GTG GAG LEU LYS ARG LEU ASP ASN LEU HIS ARG CYS LEU ALA ASP VAL VAL GLU 65 70 75 770 780 790 800 810 GAC GGC GTC CCC GGT GAC TTC ,ATC GAG ACC GGG GTG TGC CGC GCG CCG ASP GLY VAL PRO GLY ASP PHE ILE GLU THR GLY VAL CYS ARG ALA PRO 80 85 90 820 830 840 850 860 TGC ATC TTC GCC CGC GGA CTG CTG AAC GCG TAC GGC CAG GCC GAC CGC CYS ILE PHE ALA ARG GLY LEU LEU ASN ALA TYR GLY GLN ALA ASP ARG 95 100 105 870 880 890 900 910 ACC GTC TGG GTC GCC GAC TCC TTC CAG GGC TTT CCC GAG CTG ACC GGG THR VAL TRP VAL ALA ASP SER PHE GLN GLY PHE PRO GLU LEU THR GLY 110 115 120 O5 920 930 940 950 960 TCC GAC CAC CCG CTG GAC GTC GAG ATC GAC CTC CAC CAG TAC AAC GAG SER ASP HIS PRO LEU ASP VAL GLU JLE ASP LEU HIS GLN TYR ASN GLU 125 130 135 140 970 980 990 1000 GCC GTG GAC CTG CCC ACC AGC GAG GAG ACC GTG CGG GAG AAC TTC GCC ALA VAL ASP LEU PRO THR SER GLU GLU THR VAL ARG GLU ASN PHE ALA 145 150 155 (HO6808A 232 1010 1020 1030 1040 1050 CGG TAC GGG CTG CTC GAC GAC AAC GTC CGT TTC CTG GCG GGG TGG TTC AEG TYR GLY LEU LEU ASP ASP ASN VAL ARG PHE' LEU ALA GLY TRP PHE * 160 165 170 \ 1060 1070 1080 1090 1100 AAG GAC ACC ATG CCG GCT GCG CCC GTG AAG CAG CTC GCG GTG ATG CGC LYS ASP THR MET PRO ALA ALA PRO VAL LYS GLN LEU ALA VAL MET ARG 10 175 180 • 185 1110 1120 1130 1140 1150 CTG GAC GGC GAC TCC TAC GGC GCC ACC ATG GAT GTG CTC GAC AGC CTG " LEU ASP GLY ASP SER TYR GLY ALA THR MET ASP VAL LEU ASP SER LEU 15 * 190 195 200 1160 1170 1180 1190 1200 TAC GAG CGG CTG TCG CCG GGC GGT TAC GTC ATC GTC GAC GAC TAC TGC TYR GLU ARG LEU SER PRO GLY GLY TYR VAL ILE VAL ASP ASP TYR CYS ~ 205 • 210 215 220 G>- 1210 1220 1230 1240 ATC CCG GCC TGC CGC GAG CGG TGC ACG ACT TCC GCG ACC GGC TCG GCA ILE PRO ALA CYS ARG GLU ARG CYS THR THR SER ALA THR GLY SER ALA 225 230 235 1250. 1260 1270 1280 1290 ■ :TCC GCG ACA CGA TCC ACC GGA TCG ACC GCC AGG GCG CTA TTG GCG GCA SER ALA THR ARG SER THR GLY SER THR ALA ARG ALA LEU LEU ALA ALA 30 .. r. 240 245 250 rbaOBA 232 6 85 O 1300 1310 1320 1330 1340 CAG CGG CTG AGT CGT TCC GCC CGA GAG CCC GAC GAG AGC AGG AGA TAT GLN ARG LEU SER ARG SER ALA ARG GLU PRO ASP GLU SER ARG ARG TYR • 255 260 265 \ 1350 1360 1370 1380 1390 GCG AGA CAC GAC GCG CCC GCX CGG CAT TGA GGG AGC GTG GGT GAT CCA ALA ARG HIS ASP ALA PRO ALA ARG HIS 10 270 275 1400 • . 1410 1420 1430 1440 GCC GGA GAT CCA TCC GGA CCG GCG CGG CGA GTT CCA CGC GTG GTT CCA © fm>r680&A 232685 o ©' 1450 1460 1470 1480 GAG CCA' GCC GAG TTC CGG CGG CTG ACC GGT CAC TCC TTC TCC GTG CCG " N 1490 1500 1510 1520 1530 CAG GTC GTC AAT ATC GCG TGT CCC GGA AAG GCG CCG CTG CGG CAT CCA 1540 1550 ' 1560 1570 1580 CTT CTG CCG AGG TGC CAC CGG GCC GAG GCC AAG TAC AGC GGC GTG TGT 1590 1600 1610 1620 1630 GCA GGG CGC CGG TGT CGA GGT CGT CGT CGA CGC GCC GGT GTC GAG GTC 1640 GTC GTC GAC-3' wherein A is deoxyadenyl residue; G is a deoxyguanyl residue; C is a deoxycytidyl residue; and T is a thymidyl residue. The structural gene, as indicated above, begins at residue 541 and continues through to residue v_^0 1371, terminating with the'stop codon located at residue 1372. The amino acid sequence of the tylF structural gene is that indicated under the corresponding nucleotide sequence. As those skilled in the art will recognize, because of the degeneracy of the genetic code, equivalent sequences to that specifically provided above can be obtained which -"""N 's^/25 will encode the same tylF gene product. The means for obtaining such equivalent sequences will be familiar to those skilled in the art. Further, that a specific sequence is provided is not to be construed as limiting the invention in any way.

X-6808A 232685 As described in New Zealand Patent Specification No. 219694 Streptomyces fradiae strains can be cultured in a number of ways using any of several different media. Carbohydrate sources that are preferred in a 25 culture medium include, for example, molasses, glucose, dextran, and glycerol, and nitrogen sources include, for example, soy flour, amino acid mixtures, and peptones. Nutrient inorganic salts are also incorporated into the medium and include the customary salts capable of 30 yielding sodium, potassium, ammonium, calcium, phosphate, chloride, sulfate, and like ions. As is necessary for the growth and development of other microorganisms, essential trace elements are also added. Such trace elements are commonly supplied as impurities X-6808A 232685 incidental to the addition of other constituents of the medium. S. fradiae strains are grown under aerobic culture conditions over a relative wide pH range of about 5.5 to 8 at temperatures ranging from about-25° to • 5 37°C. In particular, tylosin can be produced by cultivation of tylosin-producing strains of, for example, S. fradiae such as those containing the vectors provided by the present invention. The culture medium employed can be any one of a number of media since the organism is 10 capable of utilizing many energy sources. However, for economy of production, maximum yields of antibiotic, and ease of isolation of the antibiotic, certain culture media are preferable. The media which are useful in the production of tylosin include an assimilable source of 15 carbon such as glucose, sucrose, fructose, starch, glycerine, molasses, dextrin, brown sugar, corn steep solids, and the like. The preferred sources of carbon are glucose and starch. Additionally, employable media include a source of assimilable nitrogen such as linseed 20 meal, tankage, fish meal, cotton seed meal, oatmeal, ground wheat, soybean meal, beef extract, peptones (meat or soy), casein, amino acid mixtures, and the like. Preferred sources of nitrogen are soybean meal, casein, and corn steep solids.

Mineral salts, for example, those providing sodium, potassium, ammonium, calcium, magnesium, cobalt, sulfate, chloride, phosphate, carbonate, acetate, and nitrate ions, and a source of growth factors such as distillers1 solubles and yeast extract, can be incorpo-30 rated into the media with beneficial results. ^ 232685 X-6808A -56- As is necessary for the growth and development of other microorganisms, essential trace elements should also be included in the culture medium for growing the microorganisms employed in this invention. Such trace 5 elements are commonly supplied as impurities incidental \ to the additional of the other .Constituents of the medium.

The initial pH of the culture medium can be varied widely. However, it has been found that the 10 initial pH of the medium desirably is between about pH .5 and about pH 8.0, and preferably is between about pH 6.5 and about pH 7.0. As has been observed with other organisms, the pH of the medium gradually increases throughout the growth period of the organism during 15 which time tylosin is produced, and may attain a pH from about pH 7.2 to about pH 8.0 or above, the final pH being dependent at least in part on the initial pH of the medium, the buffers present in the medium, and the period of time the organism is permitted to grow. 20 Submerged, aerobic cultural conditions are the conditions of choice for the production of large amounts of tylosin. For preparation of relatively small amounts, shake flasks and surface culture in bottles can be employed, but for the preparation of large amounts, 25 submerged aerobic culture in sterile tanks is preferred. The medium in the sterile tank can be inoculated with a sporulated suspension. However, because of the growth lag experienced when a sporulated suspension is used in the inoculum, the vegetative form of the culture is 30 preferred to avoid the pronounced growth lag, thereby 232685 X-6808A "57- permitting a more efficient use of the fermentation equipment. Accordingly, it is desirable first to produce a vegetative inoculum of the organisms by inoculating a relatively small quantity of culture ^5 medium with the spore form of the organism, and when a young, active, vegetative inoculum has been obtained, to transfer the vegetative inoculum aseptically to the large tank. The medium in which the vegetative inoculum is produced can be the same or a different medium than 10 that utilized for the iarge scale production of tylosin.

The organisms grow best at temperatures in a range of about 25°C to about 37°C. Optimal tylosin production appears to occur at a temperature of about 26-30°C.

As is customary in submerged culture process es, sterile air is blown through the culture medium. For efficient growth of the organism and tylosin production, the volume of air employed in the tank production of tylosin preferably is upwards of 0.1 volume of air 20 per minute per volume of culture medium. Efficient- growth and optimal yields of tylosin are obtained when the volume of air used is at least one volume of air per minute per volume of culture medium.

The concentration of tylosin activity in the 25 culture medium can readily be followed during the fermentation period by testing samples of the culture medium for their inhibitory activity against the growth of an organism known to be inhibited in the presence of tylosin.

«) X-6808A 2326 In general, after inoculation, maximum production of tylosin occurs within about 2 to 7 days when submerged aerobic culture or shake flask culture is , employed, and within about 5 to 10 days when surface 5 culture is used.

\ If desired, the mycelium and undissolved solids are removed from the fermentation broth by conventional means such as filtration or centrifugation. If desired, the tylosin is removed from the filtered or 10 centrifuged broth by employing adsorption or extraction techniques familiar to those skilled in the art.

For the extraction of tylosin from the filtered broth, water-immiscible, polar, organic solvents are preferred, such including esters of fatty acids, for 15 example, ethyl acetate and amyl acetate; chlorinated hydrocarbons, for example, chloroform ethylene dichlo-ride, and trichloroethylene; water-immiscible alcohols, for example, butyl and amyl alcohols; water-immiscible ketones, for example, methyl isobutyl ketone and methyl 20 amyl ketone; and others, for example,' diethyl ether and methyl propyl ether. Other solvents of similar character can also be employed. Chloroform and amyl acetate are the presently preferred extraction solvents- For the recovery of tylosin by adsorption 25 techniques, various absorbants and ion exchange resins can be used, for example, carbon, silica gel, alumina, and ion exchange resins of acidic character such as "XE" 64 and "IRC" 50 (weakly acidic cation exchange resins sold by Rohm & Haas Company), carboxymethyl cellulose 30 resin, and "Dowex" 50 (a strongly acidic cation exchange X-6808A 2326 resin sold by The Dow Chemical Company). The tylosin can be adsorbed on one of the above or similar adsorbents from a solution' in chloroform, acetone, benzene or other suitable solvents. The adsorbed tylosin can then 5 be suitable solvents. The adsorbed tylosin can then be \ eluted from the adsorbent by suitable elution techniques such as by washing the adsorbent on which the tylosin is adsorbed, with a lower alcohol, for example, methanol or ethanol, or with a lower alcohol containing up to about 10 50 percent of a lower ketone, for example, acetone.

The -organic solvent extract obtained by the preferred extraction method can be directly evaporated to dryness to provide crude tylosin. Alternatively the organic solvent extract can be used to provide purified 15 tylosin by concentration in vacuo the organic solvent extract of tylosin by decolorizing the concentrate with carbon, and by precipitating the tylosin by the addition of a non-polar solvent, for example, petroleum ether. The precipitate which is thus obtained is a solid, 20 purified tylosin which is usually amorphous. The amorphous precipitate can be crystallized by employing one of'the crystallizing solvents mentioned above. Alternatively, tylosin can be recovered from a tylosin-containing organic extract, by adsorption 25 chromatography, and by recovery of the absorbed tylosin from the absorbent by elution.

Other means for preparing the desired product from the culture medium will be recognized by those skilled in the art. ^ 232 6 85 X-6808A -60- W fa V W The acid addition salts of tylosin can be formed.with mineral acids, for example, sulfuric, f"*) hydrochloride and nitric acid, and with organic acids, for example, tartaric, gluconic, oxalic and acetic acid. • 5 The acid addition salts can be prepared by dissolving \ the free base of tylosin in a solvent in which it is soluble, such as acetone or ether, and adding to the <3^ ' solution an equimolar amount of the appropriate acid.

The salt which is formed usually precipitates out of 10 solution. In the event the salt does not precipitate, it can be recovered by evaporating the solution to a smaller volume to permit precipitation, or by adding a miscible solvent in which the salt is not soluble.

The following non-limited examples are provided to 15 further illustrate the invention. Sources of reagents are provided merely for convenience and in no way limit the invention.

O Example 1 Isolation of Plasmid pHJL280 A. Culture of E. coli K12 HB101/pHJL280 Lyophils of E. coli K12 HB101/pHJL280 can be obtained from the NRRL under the accession number NRRL B-18043. The lyophilized cells are streaked onto L-agar plates (L agar contains 10 g of Bacto Tryptone, 5 g of Bacto Yeast Extract, 10 g of NaCl, 2 g of glucose, and v 'V\ 232685 X-6808A -&1" g of agar per liter) containing 50 pg/ml ampicillin to obtain a single-colony isolate of E. coli K12 o HB101/pHJL280. One such colony was used to inoculate 100 ml of L broth (L broth is L agar without the agar), ■ 5 which was then incubated aerobically at 37°C overnight \ (about 16 hours). The following morning, the cells were harvested by centrifugation at 10,000Xg for 10 minutes-O The ~1 g of cells obtained by this procedure are used to 'prepare plasmid pHJL280 DNA in substantial accordance 10 with the procedure described below.

B. Plasmid Isolation The cell pellet obtained in Example 1A was 15 resuspended in 10 ml of a solution composed of 25% sucrose and 50 mM Tris-HCl at a pH = 8.0. About 1 ml of a 10 mg/ml solution of lysozyme in 50 mM Tris-HCl at a pH = 8.0 was added to the cell suspension, and the resulting mixture was incubated on ice for 5 minutes. 20 About 4 ml of 0.25 M EDTA, pH = 8.0, were then added to the cell suspension, and incubation on ice^jwas continued for another 5 minutes. About 16 ml of lysis solution (lysis solution contains 0.4% deoxycholate; 1% Brij58 (Sigma Chemical Co., P.O. Box 14508, St. Louis, MO 25 63178); 0.05 M Tris-HCl, pH = 8.0; and 0.0625 M EDTA) were added to the lysozyme-treated cells, and the resulting mixture was incubated at 37°C for 15 minutes.

The cell lysate was cleared by centrifugation at 48,000Xg for 25 minutes. The supernatant was decant-30 ed into a separate tube, to which was added 0.1 volume \ X-6808A 23 2 6 85 of 3.0 M NaOAc at a pH = 8.0 and 0.64 volume of isopro-pyl alcohol. The DNA precipitate was collected by centrifugation at 20,000Xg for 10 minutes and then redissolved in 0.1 volume of TE buffer (10 mM Tris-HCl, - 5 pH = 7.8, and 1 mM EDTA). The solution of DNA was \ incubated at 65 °C for 30 minutes and then purified by equilibrium-density-gradient ultracentrifugation in CsCl and propidium diiodide. The plasmid pHJL280 DNA obtained by this. procedure was dissolved in TE buffer at a concentration of about- 1 ^g/pl. A. restriction site map of plasmid pHJL280 is presented in Figure 2 of the accompanying drawings.

Example 2 Isolation of Plasmids pHJL284, pHJL309, PHJL311, and pHJL315 Lyophils of the E. coli strains harboring ' plasmids pHJL284, pHJL309, pHJL311, and pHJL315 can be obtained from the NRRL under the accession numbers listed in Table X. The desired plasmids are each obtained and purified from the lyophilized cells in substantial accordance with the teaching of Example 1.

Restriction site maps of the plasmids are presented in Figures 2-6 of the accompanying drawings.

X-6808A 232685 Example 3 Construction of Streptomyces fradiae GS28/pHJL280 5 A culture of Streptomyces fradiae GS28 was \ inoculated into -20 ml of trypticase-soya broth (TSB) and incubated in a water-bath incubator at 29°C at 260 rpm overnight (about 16 hours). The culture was homogenized using a homogenizing vessel (Thomas Scientific, 10 Swedesboro, NJ) and a -T-Line laboratory stirrer and then fragmented using a Sonifier Cell Disruptor (Heat Systems Ultrasonics, Inc.) for 7 seconds at 76 Watts. Four ml of the homogenized, fragmented'culture were inoculated into 20 ml of TSB (BBL) containing 0.3% weight by volume 15 glycine, and.the culture was .again incubated overnight at 29°C. The following morning, the culture was homogenized and recultured as described above. After this • third overnight incubation, the culture was homogenized, collected, and then washed twice with P media. P media 20 .was prepared by adding 103-g of sucrose to 0.25 g of K2SC>4 and 2.03 g of MgCl2-6H20" and then adding deionized water to a final volume of 700 ml. The mixture was then sterilized, and to each 70 ml of solution, about 10 ml each of 0.05 g KH2PC>4/100 ml of deionized water; 2.78 g 25 CaCl2/100 ml of deionized water; and 0.25 M TES (2- ([tris- (hydroxymethyl )methyl] -amino )ethanesulfonic acid)) at a pH = 7.2 were added.

The cell pellet was resuspended in 15 ml of P media containing 1 mg/ml lysozyme (Calbiochem, La Jolla, 30 CA 92037) and then incubated at room temperature for about one-and-one-half hours to form protoplasts. The protoplasts were gently collected by centrifugation, washed twice with P media, resuspended in 2 ml of P media, and incubated on ice until use. About 1 (jg of X-6808A 232685 plasmid pHJL280 DNA was added to about 50 pi of 1 mg/ml heparin sulfate (Sigma) and incubated on ice for about 10 minutes. Much less plasmid DNA, about 5-100 nanograms, can be used to transform Streptomyces fradiae if 5 prepared from a S. fradiae host. The procedure for \ isolating Streptomyces plasmid DNA is described in Hopwood et al., 1985, Genetic Manipulation of Streptomyces : A Laboratory Manual (John Innes Foundation, Norwich, England). The- DNA/heparin solution was first 10 added to about 200 jj 1 of protoplasts, and about 0.9 ml of a solution composed of 55% PEG 1000 (Stigma) in P medium was then added to the DNA/protoplast mixture, and the resulting mixture was gently mixed at room temperature.

The. mixture was' plated in varying aliquots onto"R2 plates using 4 ml of soft-R2-agar overlays. R2 plates contain 30 ml of R2 media and have been dried at 37°C for about 4 days. R2 media is prepared'by adding 103 g sucrose, 0.25 g I^SO^, 2 ml of" trace element 20 solution, 10.12 g MgCl2-6H20, 10.0 g of glucose, 2.0 g of L-asparagine, 0.1 g of Casamino acids, and 22 g of agar to 700 ml of water; sterilizing the resulting solution; and finally, adding 100 ml of each of the following solutions: 0.05 g KH^PO^/lOO ml of deionized 25 water; 2.22 g CaCl2/100 ml of deionized water; and 0.25' M TES, pH = 7.2. The pH of the final solution is adjusted to equal 7.2. Trace element solution contains 40 mg ZnCl2, 200 mg FeCl3~6H20, 10 mg CuCl2-2H20, 10 mg MnCl2-4H20, 10 mg Na^^O^-lO^O, and 10 mg 30 (NH4)6Mo7024*4H20 per liter. The soft-R2-agar overlays o X-6808A 23268& are prepared by adding 51.5 g of sucrose, 5.06 g MgCl2-6H20, 1.11 g CaCl2, 50 ml of 0.25 M TES at a pH = 7.2, and 2.05 g agar to enough deionized water to achieve a final volume of 500 ml. The mixture is • 5 steamed to melt the agar, decanted into 4 ml aliouots, - and autoclaved prior to use. After the transformed protoplasts had been plated, the plates were incubated at 29°C for 24 hours, and then, 4 ml of soft-R2 agar containing 25 pi of 50 mg/ml thiostrepton (E. R. Squibb, 10 Princeton, NJ 08540) were spread over the protoplasts. Incubation of the plates at 29°C was continued until regeneration was complete, usually a period of about 7-14 days, to' select for the desired £3. fradiae GS28/pHJL280 transformants. 15 The Streptomyces-fradiae GS28/pHJL280 strain was cultured and produced macrocin O-methyltransferase and tylosin at levels above that produced in the untransformed S. fradiae GS28 strain. Macrocin \ O-methyltransferase activity was assayed and determined 20 in substantial accordance with the teaching of Yeh et al., 1984, Journal of Chromatography 288:157-165. Comparison of the macrocin O-methyltransferase activities in the transformed, GS28/pHJL280, and parental, GS28, strains showed a 60-to-100-fold increase of enzyme 25 and 14-to-18-fold increase of tylosin production in the transformed strain. Tylosin production was assayed and determined in substantial accordance with the teaching of Baltz and Seno, 1981, Antimicrobial Agents and Chemotherapy 20:214-225; and Kennedy, J.H., 1983, 30 Journal of Chromatography 281:288-292.

\ X-6808A 23 2 6 85 Example 4 Construction of Streptomyces fradiae GS15/pHJL280 5 The desired strain was constructed in substan- \ tial accordance with the teaching of Example 3 except that Streptomyces fradiae GS15, rather than £. fradiae GS28, was used. The.desired strain was cultured for 72 hours, and produced macrocin O-methyl transferase and 10 tylosin at levels above that, produced in the untransformed S. fradiae GS15 strain, which produces no readily detectable tylosin.

Example 5 Construction of Streptomyces fradiae GS15/pHJL284 The desired strain was constructed in substantial accordance with the teaching of Example 4 except 20 ' that plasmid pHJL284, rather than plasmid pHJL280, was used. The desired strain was cultured and produced macrocin O-methyltransferase and tylosin at levels above, that produced in the untransformed S. fradiae GS15 strain. n X-6808A 67 23 2 6 85.

Example 6 Construction of Streptomyces fradiae GS16/pHJL280 • 5 The desired strain was constructed in substan- \ tial accordance with the teaching of Example 3 except that Streptomyces fradiae GS16, rather than S. fradiae GS28, was used. The desired strain was cultured and produced the tylE gene product, demethylmacrocin 10 O-methyltransferase, and tylosin at levels above that produced in the untransformed strain. The demethylmacrocin O-methyltransferase activity and tylosin production respectively are assayed and determined in substantial accordance with the • 15 above-referenced procedures, except that demethylmacrocin is substituted for macrocin as substrate.

Example 7 Construction of Streptomyces fradiae GS76/pHJL280 The desired strain was constructed in substantial accordance with the teaching of Example 3 except 25 that Streptomyces fradiae GS76, rather than S_. fradiae GS28, was used. The desired strain was cultured and produced the tylD and tylH gene products and tylosin at levels above that produced in the untransformed strain.

V X-6808A 232685 Example 8 Construction of Streptomyces fradiae GS48/pHJL280 5 The desired strain was constructed in substan- \ tial accordance with the teaching of Example 3 except that Streptomyces fradiae GS48, rather than S. fradiae GS28, was used. The desired strain was cultured and produced the tylD gene product and tylosin at levels 10 above that.produced in- the untransformed strain.

Example 9 Construction of Streptomyces fradiae GS52/pHJL284 The desired strain was constructed in substantial accordance- with the teaching of Example 3 except that Streptomyces fradiae GS52 and plasmid pHJL284, rather than S. fradiae GS28 and plasmid pHJL280, were 20 used. The desired "strain was cultured and produced the tylC gene product and tylosin at levels above that produced in the untransformed strain.

Example 10 Specific Activity of Rate-Limiting Enzymes and Increased Tylosin Production Using the Present Method The following Tables demonstrate the effec-30 tiveness of the present method. All transformants listed in the Tables were obtained in substantial .accordance with the procedure of Example 3. The results indicated in Tables XII and XIII were obtained from strains cultured in fermentation media (Baltz and Seno, n X-6808A 232685 1981, Antimicrobial Agents and Chemotherapy 20:214-225) that also contained 20 yg/ml thiostrepton if the strain being cultured harbored a plasmid. Note that the transformed strains listed in Tables XII and XIII are • 5 low tylosin-producing, or produce amounts of tylosin \ that are not readily detectable, and were cultured in the presence of selective pressure (thiostrepton) for plasmid maintenance as an autonomously replicating vector.

O .0 O 0 Table XII ' Specific Activity of the tylF Gene Product, Macrocin O-methyltransferase (MOMT) Transforming MOMT Specific Activity Strain Plasmid 2 days1 3 days 4 days 6 days Run 1 GS15 pHJL2104 0 0 0 0 GS15 pHJL280 1.14 .1.93 NT NT C42 None Not tested (NT) 0.35 • 0.16 NT Run 2 GS15 pHJL210 0 0 0 0 .

GS15 pHJL280 4.2 3.2 2.2 1.8 C4 None 0.8 1.0 0.9 0.9 T14053 None 0.9 1.2 1.5 1.4 Run 3 GS28 None 0 0.01 .0.03' NT GS28 pHJL210 0 0 0 NT GS28 pHJL280 0.8 0.7 ' 1.0 NT GS28 pHJL284 0.9 1.2 0.9 NT C4 None 0.2 0.6 . 0.5 NT xdays in fermentation. 2the strain from which GS15 and GS28 were derived. 3a strain derived from C4. 4the cloning vector into which the tyl genes were inserted to obtain plasmids pHJL280 and pHJL284. o O o Table XIII Specific Activity of the tylE Gene Product, Demethylmacrocin O-methyltransferase (DMOMT) ; Strain Transforming Plasmid DMOMT Specific Activity 2 days* 3 days 4 days GS16 pHJL210 0 0 0 GS16 pHJL280 ■ 1.8 :3.7 4.0 GS16 pHJL280 3.8 1.7 3.0 GS16 pHJL284 1.3 1.6 2.2 C4 pHJL210 0.7 1.3 1.5 C4 PHJL210 0.2 1.1 1.9 C4 None 0.4 1.5 1.0 23 2 6 X-6808A -72-.

The results in Table XIV were obtained from transformants of high tylosin-producing strains that were cultured post-transformation to obtain integrants, transformants in which all or part of the plasmid DNA • 5 has integrated into the genome of the host cell. Two >, methods were used to obtain the integrants. In the first method, transformants are passaged onto selective (contains thiostrepton) and nonselective plates and • incubated about 16 hours at 29°C to obtain single 10 colonies. The single'colonies on the nonselective plates that were thiostrepton-resistant on the selective plate are repassaged several times in the same manner until a single colony was found to be relatively stable . without selection- In the sfecond method for obtaining 15 integrants, the transformants were nonselectively passaged several times by transferring spores from the surface of the plate using a cotton swab. After several passages, the colonies are grown in non-selective, liquid media (TSB), homogenized, fragmented by sonica-■20 tion, diluted, and plated on selective and nonselective media to identify relatively stable integrants. Other methods of obtaining integrants are apparent to those skilled in the art, and the method is not limited to a particular method of obtaining integrants. 25 Relatively stable integrants were used to inoculate vegetative medium (complex vegetative medium contains, per liter, 10 g of corn steep liquor, 5 g of yeast extract, 5 g of soybean grits, 3 g of calcium carbonate, and 4.5 g of crude soybean oil, and the pH is 30 adjusted to 7.8 with NaOH. TSB is also a suitable n X-6808A 232685 vegetative media) without thiostrepton (no selective pressure), and the vegetative culture was used to inoculate (10% inoculum) the fermentation medium, which also lacked thiostrepton- Fermentations .were run at • 5 260 rpm at 29°C for seven days- The total macrolide v. content of the fermentation broth was measured by extraction with methanol:CHC13, reading the absorbance at 290 nm, and comparing to a standard curve. Tylosin factors were identified by spotting the fermentation 10 • broth onto silica-gel-'TLC plates and developing the plates with a solvent system of 95:5 ethylacetate:diethylamine. The concentration of individual macrolide components was the total A2go times^ the percentage of each component as determined by HPLC. \ © © © o ; Table XIV % Thiostrepton Transforming DMOMT MOMT Strain Resistant Plasmid ■ Specific Activity Specific Activity Tylosin* C4 0 None 0.59 0.14 1 C4 9.5 PHJL280 Not tested (NT) NT 1.10 C4 .9 PHJL280 NT NT 0.97 T1405 0 None ' 1.0 0.17 1.14 T1405 50 pHJL280 0.91 0.26 1.52 T1405 8.7 PHJL280 NT NT 1.21 T1405 11 PHJL280 NT NT 1.07 T1405 6.4 pHJL280 NT NT 1.21 T1405 18 pHJL280 2.5 0.43 1.60 T1405 4.6 pHJL280 NT NT 0.98 T1405 16 pHJL280 NT NT 1.07 T1405 12 PHJL280 NT • NT 1.10 T1405 18 PHJL280 . NT NT 1.28 T1405 pHJL280 NT NT 1.28 T1405 56 pHJL280 0;82 0.22 1.45 *Relative to C4 strain ft X-6808A 252685 Example 11 Preparation of Tylosin A sporulated culture of Streptomyces fradiae containing the plasmids provided by the inven tion can be produced by growing the organism on a nutrient agar slant having the following composition: Yeast extract 1.0 g Beef extract 1.0 g Hydrolyzed casein ("N-Z-Amine-Type A, " sold by the Sheffield Chemical Co.) 2 g Dextrin . 10 g Cobaltous chloride heptahydrate 7 20 mg Agar . 20 g Water 11 232685 X-6808A -76-.

The pH of the medium is adjusted to pH 7.3 by the addition of sodium hydroxide.

The slant is inoculated with spores of the desired organism and is incubated for five days at about - 5 30°C. The sporulated culture growth on the slant is \ covered with water, and the slant is scraped gently to remove the spores to provide an aqueous spore suspension. 1 ml. of the spore suspension is used to 10 inoculate under aseptic conditions a 100 ml. portion of a' sterile vegetative culture medium having the following composition: G.

Glucose 15 Soybean meal ' 15 Corn steep solids 15 Sodium chloride 5 Calcium carbonate 2 Tap water, added to make a total of volume of 1 1: The inoculated vegetative medium is incubated at about 30°C. for 48 hours, during which time the 25 incubate is shaken at the rate of 114 cycles per minute on a reciprocal shaker having a 2-inch stroke. ml. of the vegetative inoculum are used to inoculate aseptically 100 ml. portions of the following sterilized production medium contained in 500 ml. 30 Erlenmeyer flasks: Soybean meal g Casein 1 g Crude glucose syrup ml Calcium carbonate 2.5 g Sodium nitrate 3 g Tap water, added to make a total of volume of 1 1.

X-6808A £32685 The inoculated culture then is incubated for 100 hours at about 26-28°C. During the incubation period, the incubate is shaken at 114 revolutions per minute, on a reciprocal shaker having a 2-inch stroke. • 5 The pH of the starting medium is about pH 6.5, and at \ the end of the incubation period, the pH of the medium generally increases to about pH 7.5.

The fermented culture broth is filtered to remove the mycelium and other undissolved solids. The 10 filtered broth contains the tylosin. formed microorganism is produced by growing the organism on a nutrient agar slant having the following composition.

Examole 12 Alternate Preparation of Tylosin A sporulated culture of the desired trans Tomato paste-oatmeal Agar: G 20 20 15 1 1.

Tomato paste Pre-cooked oatmeal Agar Water, added to make a total volume of The slant is inoculated with spores of the organism and the inoculated slant is incubated for 9 r* X-6808A 232685 days at a temperature of about 30°C. After incubation, the sporulated culture on the slant is covered with water, and the surface of the slant is scraped gently to remove the spores to obtain an aqueous spore suspension.

Employing aseptic techniques, one-half of the inoculum obtained from one agar slant is used for inoculating a 500 ml. portion of a sterilized vegetative culture medium having the following composition contained in a 2 1. Erlenmeyer flask: 10 . ■ Corn-steep yeast I: G.

Glucose 15 Corn steep solids 5 Yeast 5 Calcium carbonate 5 Water, added to make a total volume of 1 1.

The incubation is carried on at 28°C for 48 hours with shaking at 110 cycles per minute on a recip-20 rocal shaker having a 2-inch stroke. 0.25 gal. of the vegetative inoculum from the flask is added aseptically as an inoculum to 250 gal. of the sterile corn steep yeast I medium described above contained in an iron 350 gal fermentor. 0.025 gal. of 25 Antifoam A (an antifoam product sold by The Dow Corning Company) is added to the culture medium to prevent excessive foaming, and additional quantities are added as needed during the fermentation. The inoculated medium is fermented for 24 hours at a temperature of 30 28°C. During fermentation, the medium is aerated with sterile air at a rate of 27 cubic feet per minute and is o X-6808A 2326 85 agitated with two 16-inch impellers operated at 160 revolutions per minute. .

To a 1700 gal. iron fermentor are added 1200 gal. of a medium having the following composition. • 5 \ Cora steep soy XII: Kg.

Glucose 30 Soybean oil meal 15 Corn steep solids 5 Crude soybean oil 10 Calcium carbonate ' 2 Sodium chloride 5 Water, added to make a total volume of 1000 1.

The medium is inoculated with 96 gal. of the inoculum grown in the fermentation tank. The fermentation is carried on at 28°C for four days, and any foaming is controlled by the addition as needed of 20 "Larex" No. 1 (an antifoam product sold by Swift & Company). The fermentation medium is aerated by the addition of sterile air at the rate of 128 cubic feet per minute and is agitated with two 24-inch impellers operated at 130 revolutions per minute. 25 600 pounds of "Silflo" (a diatomaceous earth filter aid sold by The Silfo Company) are added to the broth, and the mixture is filtered. The filtrate is adjusted to pH 8.5 by the addition of 20 percent sodium hydroxide, 500 gal. of chloroform are added, the mixture 30 is stirred for 30 minutes, and the chloroform layer which is in the form of an emulsion is decanted. The chloroform extraction is repeated twice with 500-gal. portions of chloroform. The chloroform emulsions which X-6808A 232685 contain the tylosin are combined and are passed through a De Laval separator to break the emulsion, and the chloroform solution is then concentrated in vacuo to a volume of 25 1. The impurities are largely removed from 5 the solution by passing it over a column 6 inches in \ diameter containing 10 kg. of activated carbon such as that sold by the Pittsburgh Coke and Chemical Co. The carbon column is washed with 16 1. of chloroform, and the combined chloroform effluents containing the tylosin 10 are concentrated in vacuo to a volume of about 2 1. The chloroform concentrate is added slowly with stirring to 20 1. of petroleum ether, the mixture is stirred for 15 ' minutes, it.is filtered to remove the white, amorphous precipitate of tylosin.

The amorphous tylpsinis crystallized by dissolving it in 355 ml. of acetone, filtering the • acetone mixture to remove a slight haze, and slowly adding the filtered acetone mixture with gentle stirring to 20 1. of water at 5°C. The aqueous, acetone solution 20 of tylosin is permitted to stand at room temperature with gentle stirring to permit the. acetone to evaporate slowly, whereupon tylosin crystallizes out. The tylosin crystals are removed by filtration and are dried in vacuo at room temperature. Tylosin has a melting point 25 of about 127-132°C.

X-6808A 232685 Example 13 Preparation of Tylosin Tartrate •5 5 g. of crystalline tylosin are dissolved in 100 ml. of acetone, and 1.5 g. of D-tartaric acid dissolved in 20 ml. of acetone are added with stirring. The solution is permitted to stand at room temperature whereupon the tartrate salt of tylosin crystallizes out 10 of the solution. The crystals of the tartrate salt of tylosin are removed by filtration, are washed with acetone, and are air-dried. The crystalline tartrate salt of tylosin melts at about 140-146°C.

Example 14 • Preparation of Tylosin Gluconate 1.03 g. glucono-delta lactone are dissolved in 20 10 ml. of water, and the aqueous solution is warmed to 85 °C. for two hours to cause hydrolysis of the lactone to gluconic acid. 15 ml. of warm methanol are added to the aqueous solution. 5 g. of tylosin dissolved in 10 ml. of methanol are added to the methanol mixture with 25 stirring. The tylosin methanol mixture is permitted to stand overnight at room temperature. The methanol is removed from the mixture by evaporation in vacuo at room temperature. After the methanol is removed, 40 ml. of water are added to the aqueous tylosin mixture. The 30 diluted mixture is filtered, and the filtrate containing the tylosin is freeze-dried, producing a white solid consisting of the gluconate salt of tylosin. Tylosin gluconate salt melts at about 114-117°C. 232685 X-6808A -82- Example 15 - Preparation of Tylosin Hydrochloride • 5 890 mg. of tylosin are dissolved in 200 ml. of \ ether. The ether mixture is acidified by the addition of 0.082 ml. of 12 N hydrochloric acid. The precipitate of the hydrochloride salt of tylosin which forms is filtered off, is washed with ether, and is dried in 10 vacuo. The hydrochloride salt of tylosin is recrystallized from an ethanol-ether mixture. The hydrochloride salt of tylosin has melting.point of about 141-145°C. r***\ (£?>> 232685

Claims (11)

1. WHAT WE CLAIM IS: 1. A DNA molecule in substantially pure form containing the DNA sequence that encodes a gene for the tylC, tylD, tylE, tylF, tylH, tylJ, tylK, tylL, or tylM biosynthetic genes.
2. 2. A DNA molecule in substantially pure form containing the DNA sequence which encodes the promoter and translational-activating sequence of the tylC, tylD, tylE, tylF, tylH, tylJ, tylK, tylL, or tylM, biosynthetic genes.
3. 3. A DNA molecule in substantially pure form containing the DNA sequence which encodes the promoter and translational-activating sequence of the tylF gene.
4. 4. A DNA molecule in substantially pure form containing the DNA sequence of claim 3 encoding the tylF promoter that is 5'-CTG TGT CAG GTC GCC CGT GGT GAC GGG CTC CGG GGC GGC GGC GCG GAC ACA GTC CAG CGG GCA CCA CTG CCC GAG GCC CCG CCG CCG CGC GGC CCG GGC CCG CGA GCT CCT GGA TGA ACT CAT GTA ACC TGG CGC GCG GGC CCG CGG GCC GCT CGA CCT GGA CGT GCA TCC AGG GGC CCG GCG CGC GCC CGG CGC GCG GCC CGG GAT CTA AGC TCG GTC CAG CGT GCA CCT GGA CAC GTG CGG GCC CTC GAG CGG GCC CGT GCA CCG GGC CGT GCA CCC GGG CGC GCG CGG GCC GAC CTG GTG CAC CCA GGT CCT GGA CTC GAG CCG GGC ACC TGG CCG GGC CGA GCT GCC CGG GAT CTA CGA GCT CCC GGG GCT CGA ACT TGA GGA CCT GGA CCT CCC-GGG ■3' wherein A is a deoxyadenyl residue; G is a deoxyguanyl residue; C is a deoxycyctidyl residue; and T is a thymidyl residue.
5. 5. A DNA molecule in substantially pure form containing the DNA - 84 - 2326 100 110 CCC GGG CGA TCG GCT CCT CCG 150 160 GGC TGA AGG GAC AGG TGC GGG CGA 200 210 CTG CGG CCC CGT CGG TGT CGT TGG 250 260 CCT TTT GTG ACG GGC GGG CGT CCC 290 300 310 GCC TCA ACG AAA ACA CCG TGT CCG 40 AGC GCC CGG ACG 90 CCC ACA GCT CGG 140 ACT GCT CGG GAG 170 180 190 CCG GCC AGG CGA TGC TGC GCC GGC 220 230 240 CGC GTG CTG CGG GCA ACA GAA' TCC 270 280 CGG ACG AGG ACA CGA CTC GCT GCG 320 330 GTG CCC AGG CCA CGA ACG GTG ACC 10 20 30 TTC GCG GGA TGG ATG CTG ACC CGG GGG TCG GCC AGC 50 60 70 80 TGA TCT GGC GGG AGA TCA GCC AGA CCG GCG CCC CGT 120 130 CCC GGA GGG CGG CGT 340 350 360 370 380 GGT CTG TGT CAG GTC GCC CGT GGT GAC GGG CTC CGG GGC GGC GGC GCG 390 400 410 420 430 GGC GGC CGA CCT TGA CAT ACC CGC GGC CGG GCT CCT CGT TCC GGC GCG 440 450 460 470 480 GCC CGC GCC GAT AGC GTC CGT CCT CAC CGG CTC CGG CGT CCG CGT CCC 490 500 510 520 CGC CGG GAC GTG CCA CCT CTC CCG ACC CCG CGA GCC GAT CGA CCC GCT 530 540 550 • 560 570 ACT GGA GGA CCC GTG GCA CCT TCC CCG GAC CAC GCC CGC GAT CTC TAC VAL ALA PRO SER PRO ASP HIS ALA ARG ASP LEU TYR 5 10 - 85 - 2326 580 590 600 610 .620 ATC GAG CTG CTG AAG AAG GTC GTC TCG AAC GTC ATC TAC GAG GAC CCC ILE GLU LEU LEU LYS LYS VAL VAL SER ASN VAL ILE TYR GLU ASP PRO 15 20 25 630. 640 650 660 670 ACC CAT GTG GCG GGG ATG ATC ACC GAC GCG TCG TTC GAC CGG ACG TCC THR HIS VAL ALA GLY MET ILE THR ASP ALA SER PHE ASP ARG THR SER 30 35 40 680 690 700 710 720 CGT GAG AGC GGC GAG GAC TAC CCC ACG GTC GCC CAC ACG ATG ATC GGC ARG GLU SER GLY GLU ASP TYR PRO THR VAL ALA HIS THR MET ILE GLY 45 50 55 - 60 730 740 750 760 CTC AAG CGT CTG GAC AAT CTC CAC CGG TGC CTC GCG GAC GTC GTG GAG LEU LYS ARG LEU ASP ASN LEU HIS ARG CYS LEU ALA ASP VAL VAL GLU 65 70 75 770 780 790 800 810 GAC GGC GTC CCC GGT GAC TTC ATC GAG ACC GGG GTG TGC CGC GCG CCG ASP GLY VAL PRO GLY ASP PHE ILE GLU THR GLY VAL CYS ARG ALA PRO 80 85 90 820 830 840 850 860 TGC ATC TTC GCC CGC GGA CTG CTG AAC GCG TAC GGC CAG GCC GAC CGC CYS ILE PHE ALA ARG GLY LEU LEU ASN ALA TYR GLY GLN ALA ASP ARG 95 100 105 * 870 880 890 900 910 ACC GTC TGG GTC GCC GAC TCC TTC CAG GGC TTT CCC GAG CTG ACC GGG THR VAL TRP.
6. VAL ALA ASP SER PHE GLN GLY PHE PRO GLU LEU THR GLY 110 115 120 2326 920 930 940 950 960 TCC GAC CAC CCG CTG GAC GTC GAG ATC GAC CTC CAC CAG TAC AAC GAG SER ASP HIS PRO LEU ASP .
7. VAL GLU ILE ASP LEU HIS GLN TYR ASN GLU 125 130 135 140 970 980 990 1000 GCC GTG GAC CTG CCC ACC AGC GAG GAG ACC GTG CGG GAG AAC TTC GCC ALA VAL ASP LEU PRO THR SER GLU GLU THR VAL ARG GLU ASN PHE ALA 145 150 155 1010 1020 1030 1040 1050 CGG TAC GGG CTG CTC GAC'GAC AAC GTC CGT TTC CTG GCG GGG TGG TTC ARG TYR GLY LEU LEU ASP ASP ASN VAL ARG PHE LEU ALA GLY TRP PHE 160 165 170 1060 1070 1080 1090 1100 AAG GAC ACC ATG CCG GCT GCG CCC GTG AAG CAG CTC GCG GTG ATG CGC LYS ASP THR MET PRO ALA ALA PRO VAL LYS GLN LEU ALA VAL MET ARG ' 175 180 185 1110 1120 1130 1140 1150 CTG GAC GGC GAC TCC TAC GGC GCC ACC ATG GAT GTG CTC GAC AGC CTG LEU ASP GLY ASP SER TYR GLY ALA THR MET ASP VAL LEU ASP SER LEU 190 ■ 195 200 1160 1170 1180 . 1190 1200 TAC GAG CGG CTG TCG CCG GGC GGT TAC GTC ATC GTC GAC GAC TAC TGC TYR GLU ARG LEU SER PRO GLY GLY TYR VAL ILE VAL ASP ASP TYR CYS 205 210 215 220 1210 1220 1230 1240 ATC CCG GCC TGC CGC GAG CGG TGC ACG ACT TCC GCG ACC GGC TCG GCA ILE PRO ALA CYS ARG GLU ARG CYS THR THR SER ALA THR GLY SER ALA 225 230 235 - 87 - 232685 1250 1260 1270 1280 1290 TCC GCG ACA CGA TCC ACC GGA TCG ACC GCC AGG GCG CTA TTG GCG GCA SER ALA THR ARG SER THR GLY SER THR ALA ARG ALA LEU LEU ALA ALA 240 245 250 . 1300 1310 1320 1330 1340 CAG CGG CTG AGT CGT TCC GCC CGA GAG CCC GAC GAG AGC AGG AGA TAT GLN ARG LEU SER ARG SER ALA ARG GLU PRO ASP GLU SER ARG ARG TYR 255 260 265 1350 1360 1370 1380 • 1390 GCG AGA CAC GAC GCG CCC GCT CGG CAT TGA GGG AGC GTG GGT GAT CCA ALA ARG HIS ASP ALA PRO ALA ARG HIS 270 275 1400 1410 1420 1430 1440 GCC GGA GAT CCA TCC GGA CCG GCG CGG CGA GTT CCA CGC GTG GTT CCA 1450 1460 1470 1480 GAG CCA GCC GAG TTC CGG CGG CTG ACC GGT CAC TCC TTC TCC GTG CCG 1490 1500 1510 1520 1530 CAG GTC GTC AAT ATC GCG TGT CCC GGA AAG GCG CCG CTG CGG CAT CCA 1540 1550 1560 1570 1580 CTT CTG CCG AGG TGC CAC CGG GCC GAG GCC AAG TAC AGC GGC GTG TGT 1590 1600 1610 1620 1630 GCA GGG CGC CGG TGT CGA GGT CGT CGT CGA CGC GCC GGT GTC GAG GTC 1640 GTC GTC GAC-3'. wherein A is a deoxyadenyl residue; G is a deoxyguanyl residue; C is a deoxycytidyl residue; and T is a thymidyl residue and wherein R is a sequence of deoxyribonucleotide that is complementary to said DNA sequence depicted such that A is paired with T; T is paired with A; 6 is paired with C; and C is paired with G. - 88 - 232685
8. 8. A peptide in substantially pure form having the amino acid sequence encoded by nucleotides 541 to 1371 of the tylF gene defined in claim 7
9. 9. A DNA molecule in substantially pure form as claimed in any one of claims 1 to 5 substantially as herein described with reference to any example thereof.
10. 10. The tyl-F gene as claimed in claim 6 or claim 7 substantially as herein described with reference to any example thereof.
11. 11. A peptide as claimed in claim 8 substantially as herein • described with reference to any example thereof. Ey fcUs/Their authorised Agent A.J. PA.RK-& SON ■'-P f? ! ^ C